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Abstract 
Studies suggest that co-3 polyunsaturated fatty acids (PUPAs) are beneficial in inhibiting the 
growth of cancer cells and may enhance the cytotoxicity induced by certain chemotherapeutic 
agents. It is known that seal oil is rich in co-3 PUPAs. The effect of seal oil and its role on the 
cytotoxicity and apoptosis induced by paclitaxel was, therefore, investigated in breast cancer cell 
lines, MCF-7 and MDA-MB-231. 
MCF-7 and MDA-MB-231 cells were respectively treated with seal oil, paclitaxel, and 
paclitaxel in combination with seal oil. Cytotoxicity was evaluated by MTT assay. Apoptosis was 
investigated by morphological changes and DNA strand break assay. Western blot assay was used 
to assess the expression of p53 and Bcl-2 proteins. The lipid peroxide products were measured by 
thiobarbituric acid reactive substances (TEARS) assay and the intracellular lipid composition was 
determined by gas chromatography (GC). 
MTT assay showed that seal oil induced cell death and enhanced paclitaxel cytotoxicity in both 
cell lines. The IC50 values of paclitaxel in MCF-7 and MDA-MB-231 cells were reduced 3.3- and 
2.4-fold, respectively, by the inclusion of 0.016% seal oil. Morphological assessment and DNA 
strand break assay indicated that more cells treated with paclitaxel in combination with seal oil 
underwent apoptosis than that with paclitaxel alone treatment. Seal oil alone was also found to 
induce apoptosis in both cell lines. Western blot showed that the expression of apoptosis inhibitor 
Bcl-2 protein in both cell lines was down-regulated by seal oil and was inhibited further when cells 
were treated with paclitaxel in combination with seal oil. GC assay determined that the total 
ii 
PUFAs increased significantly in the intracellular lipid composition following incubation with 
seal oil, which may be responsible for the increased lipid peroxides found in cells incubated under 
the same conditions. 
In addition to seal oil, Intralipid®, which is a soybean oil emulsion mainly containing co-6 
PUFAs, was also studied for its cytotoxicity and apoptosis induction. It was found that soybean oil 
induced cell death in the MCF-7 cell line but promoted cell growth in the MDA-MB-231 cell line. 
Soybean oil did not induce apoptosis as characterized by morphological assessment. 
In conclusion, seal oil was found to induce apoptosis, and to enhance the cytotoxicity and 
apoptosis induced by paclitaxel in both breast cancer cell lines, which may be due to its ability to 
down-regulate the expression ofBcl-2 protein and to produce lipid peroxides. The beneficial effect 
exerted by seal oil suggests that seal oil may have a great potential in the management of cancer. 
Key words: polyunsaturated fatty acids (PUFAs); seal oil emulsion; Intralipid®; paclitaxel; breast 
cancer; MCF-7 cell line; MDA-MB-231 cell line; apoptosis; cytotoxicity; MTT assay; Hoechst 
staining; TUNEL assay; Annexin-V-FLOUS staining; Western blotting assay; TBARS assay; GC 
assay; p53; Bcl-2; lipid peroxide products 
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Chapter 1 Introduction 
1.1 Polyunsaturated fatty acids (PUFAs) and cancer 
1.1.1 Biochemistry ofPUFAs 
PUFAs are a series of unsaturated fatty acids with even numbers of carbon atoms, between 
18 and 22, and 1 to 6 double bonds in the carbon skeleton. PUFAs and their metabolites have a 
variety of physiological roles including energy provision, membrane construction, and synthesis 
of cell signalling molecules and regulation of gene expression (Jump et al., 1996 and Diggle, 
2002). The hydrophobic biological membrane made by fatty acyl chains acts as a barrier and 
communication boundary to regulate movements and metabolic products across the membrane. 
PUFAs in the membrane can also interact with proteins located in the membrane such as 
enzymes, receptors and transporters to conduct cellular signals. 
PUFAs comprise two forms: non-esterified fatty acids or free fatty acids and esterified fatty 
acids. Esterified PUFAs exist as glycerol esters, such as phospholipids and triglycerides, which 
are the major composition of cell membrane. Figure 1.1 shows an example of a phospholipid in 
which the second hydroxyl group of the glycerol is esterified with a PUFA and the other two 
hydroxyl groups are esterified to a phosphate and either to a saturated or monounsaturated fatty 
acid or an aldehyde in its enolic form, respectively (Spiteller, 2003) (Figure 1.1). 
R: a saturated or monounsaturated fatty acid or an aldehyde 
Figure 1.1 Structure of an esterified polyunsaturated fatty acid 
(Adapted from Spiteller, 2003) 
The designation of PUFAs is characterized by the number of carbon atoms, the number of 
double bonds and the position of the first double bond starting from the methyl terminal of the 
molecule. For example, 18:2w-6 refers to linoleic acid (LA) with a chain length of 18 carbon 
atoms, 2 double bonds, and with the first double bond being at the sixth carbon atom from the 
methyl terminal. Based on the position of the first double bond starting from the methyl terminal 
of the carbon chain, PUFAs can be classified into two main classes, co-6 class and co-3 class, in 
which the first double bond starts at the sixth and third carbon atom from the methyl terminal, 
respectively. The co-6 PUFAs exist mainly in plant sources such as soybean oil, including LA, 
y-linolenic acid (y-LA) (18:3co-6) and arachidonic acid (AA) (20:4co-6). The co-3 PUFAs are 
rich in marine sources such as fish oil. They commence with a-linolenic acid (a-LA) (18:3co-3) 
and mainly include eicosapentaenoic acid (EPA) (20:5co-3) and docosahexaenoic acid (DHA) 
(22:6co-3). 
2 
The first member of co-6 class, LA, which is the most abundant PUFA found in plant seeds 
and oil, is synthesized by terrestrial plants; however, the first member of co-3 class, a-LA, is 
synthesized by cold-water vegetation, and fish and sea animals that feed on these organisms 
convert it into the two most abundant members in the class, EPA and DHA. In animals and 
humans, LA and a-LA must be obtained from their diet because mammalian organisms lack 
~-12 and ~-15 desaturase enzymes that are required for the synthesis of LA and a-LA (Spector 
and Bums, 1987). Therefore, both co-6 and co-3 PUFAs are considered as essential fatty acids. 
Mammalian cells can convert the PUFAs within each class, but they cannot convert co-3 class 
into co-6 class or vice versa because they do not possess the necessary enzymes (Spector and 
Bums, 1987, Noguchi et al., 1995 and Simopoulos, 2002). In biological systems, LA or a-LA 
subjects to elongation, desaturation and conversion by elongases and desaturases to yield longer 
and more unsaturated fatty acids. In humans, LA is readily converted to AA via y-LA; however, 
a-LA is not efficiently converted to EPA and DHA. Both AA and EPA are the substrates of 
eicosanoid metabolism, which produces prostaglandins (PGs) and thromboxanes (TXs) by 
cyclooxygenases (COXs), and leukotrienes (LTs) and hydroxyeicosatetraenoic acids (HETEs) 
by lipoxygenases (LOXs) and cytochrome P450, respectively. These eicosanoids behave as 
"local hormones" and chemical transmitters for a variety of intercellular and intracellular 
signals. Figure 1.2 shows the structures and relationship of the main fatty acids in each class and 
their metabolic pathways. 
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Figure 1.2 Pathways of elongation, desaturation and metabolism of dietary fatty acids 
(Adapted from Noguchi et al., 1995 and Tapiero et al., 2002) 
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In humans, fatty acids obtained from the diet or extrahepatic tissues enter hepatocytes and 
are rapidly converted to fatty acid acyl-coenzyme A (FA-CoA) thioesters that are substrates for 
further elongation, desaturation, lipid synthesis, ~-oxidation, mediator synthesis and protein 
acylation reactions (Stulnig, 2003). They are processed to form complex lipids, such as 
triacylglycerols and phospholipids, or are diverted to oxidation in mitochondria, peroxisomes 
and the endoplasmic reticulum. Complex lipids are assembled into lipoprotein complexes and 
secreted in the form of very low-density lipoproteins (VLDL) to extrahepatic tissues, such as 
adipose tissue, where fatty acids are assembled into triacylglycerols for storage (Jump et al., 
1996). 
1.1.2 Effect of PUFAs on cancers 
1.1.2.1 ro-3 PUFAs versus ro-6 PUFAs 
PUFAs not only play various essential roles in the physiological processes but also have 
pathophysiological activities on nervous system, cardiovascular disease, inflammatory disease, 
immune system and especially some cancers. Exogenous PUFAs have been investigated in 
different kinds of cancer including breast, colon and prostate cancer. With breast cancers, 
hormone dependent cell lines, MCF-7, ZR-75 and T-47-D, and hormone independent cell lines, 
MDA-MB-231, HBL-100, have been treated with co-6 and co-3 PUFAs. The results showed that 
the cell growth was inhibited by co-3 PUFAs, and EPA and DHA were the most effective fatty 
acids in the arresting of cell growth (Chajes et al., 1995 and Germain et al., 1998). When 
athymic nude mice bearing with MCF-7 or MDA-MB-231 cancer cells were fed with fish oil or 
corn oil diet for 6-8 weeks, it was found that cancer growth was suppressed in mice consuming 
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-fish oil diet as compared with mice fed with com oil, which is rich in co-6 PUFAs. The data 
showed that the greater the amount of dietary fish oil consumed, the greater the cancer 
suppression observed. At the end of the experiments, it was found that the mean tumour volume 
of mice in the fish oil group was the least and that in the com oil group was the largest (Pritchard 
et al., 1989, Gonzalez et al., 1991 and Gonzalez et al., 1993). These results suggested that diet 
high in co-3 PUFAs inhibited tumour cell growth but co-6 PUFAs were associated with tumour 
cell proliferation. Similar results were also found in humans where a higher ratio of co-6 to co-3 
consumed in the diet was associated with a higher risk of breast cancer occurrence in women 
(Bagga et al., 1997 and Klein et al., 2000). 
Several studies have also shown that co-3 PUFAs inhibit the growth of some other cancers 
while co-6 PUFAs promote cancer development. For example, it has been reported that diet high 
in co-6 PUFAs could stimulate prostate cancer development. On the contrary, long chain co-3 
PUFAs such as DHA and EPA could inhibit prostate cell growth in vitro and in vivo 
(Giovannucci et al., 1993; Motaung, et al., 1999 and Chung et al., 2001). The cytotoxicity of 
PUFAs investigated in HL-60 leukaemic cell line (Arita et al., 2003) and HT-29 colon cancer 
cells (Chen et al., 2000) revealed that co-3 PUFAs had an inhibitory effect on the growth of these 
cancer cells. When cytotoxicity caused by various PUFAs was examined by flow cytometric 
analysis, results showed that the cytotoxicity was related to the chain length of the PUFAs and 
the number of double bonds in them, and DHA and EPA were shown to be most potent (Lima et 
al., 2002). 
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1.1.2.2 PUFAs in combination with chemotherapy and radiotherapy 
A number of studies have shown positive effect of exogenous PUFAs on chemotherapy and 
radiotherapy both in cell culture and in tumour-bearing animals (Bums et al., 1986; Zulstra et 
al., 1987; Petersen et al., 1992; Shao et al., 1995; Germain et al., 1998 and Conklin, 2002). 
Chemotherapeutic drugs investigated include the anthracyclines such as doxorubicin (DOX), 
the epipodophyllotoxins, the camptothecins, the platinum coordination complexes and 
alkylating agents. Cancer types investigated included breast cancer, ovarian cancer, and 
leukemia and lymphoma cells. It was found that in comparison with chemotherapeutic drug 
alone, the cytotoxicity of chemotherapeutic drugs was enhanced when PUFAs such as DHA, 
EPA, y-LA, AA and LA were used in combination with the chemotherapeutic drugs (Germain et 
al., 1998, Yamamoto et al., 1999 and Conklin, 2002). In athymic mice with human mammary or 
lung carcinoma, these anti-cancer drug treatments resulted in a greater inhibition of tumour 
growth when mice were fed fish oil (varying from 4-20 %) enriched diet (Conklin, 2002). In 
addition to chemotherapy, PUFAs can also enhance the sensitivity of cancer cells to radiation 
therapy (Vartak et al., 1997). It was reported that an improved response to radiotherapy as well 
as chemotherapeutic agents was found in patients who received 5-7 g/day of co-3 PUFAs 
(Barozio et al., 1998). 
1.1.3 Possible mechanisms of PUFAs activities on cancers 
1.1.3.1 Modulation of PUFAs in cell membrane 
Since PUFAs participate in membrane construction and cell proliferation, the enrichment of 
PUFAs in membrane has potential impacts on the normal barrier function and the physical and 
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biochemical characteristics of the membrane. It has been reported that plasma membranes 
enriched in PUFAs have lower order parameters, or greater fluidity and higher permeability 
(Spector and Burns, 1987 and William et al., 1993). These changes might cause loss of 
surrounding lipid matrix, change of the accessibility of binding site, alteration of the tightness of 
binding ligand, the size of the transmembrane channel and the signal transduction of receptors. 
In addition, because a number of transport and receptor proteins locate in the membrane and 
across the lipid bilayer, changing in membrane composition may affect the properties of these 
proteins. Such effects have more important consequences for tumour cells by influencing the 
transport and uptake of nutrients and chemotherapeutic drugs, which enter into cells by 
carrier-mediated and energy-requiring transporters (Spector and Burns, 1987). When PUFAs are 
used in combination with anti-cancer drugs, the composition of fatty acids in the tumour cell 
membrane may be altered as a result of incorporation of PUFAs. This change may assist drugs 
to flux across the cell plasma membrane and increase the intracellular drug concentration 
leading to a reduced resistance and increased sensitivity to chemotherapy (Ikushima et al., 1991; 
Germain et al., 1998 and Conklin, 2002). 
1.1.3.2 Generation of lipid peroxidation products from PUFAs 
It is conceivable that as the first defence line PUFAs in the cell membrane are highly 
susceptible to oxidative stress in biological systems, producing reactive oxygen species (ROS) 
(Table 1.1). The transformation of these products can be used as an economical way to transit 
the communication signals generated in the membrane to cytoplasm. ROS and their derivatives 
can react with and attack almost every critical cellular macromolecule including DNA, lipids, 
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proteins and carbohydrates, and cause structural as well as functional alteration, leading to cell 
membrane damage, cellular composition and molecular architecture changes, and signalling 
disruptions (Gonzalez et al., 1993 and Conklin, 2002). For example, various potential 
compounds found among ROS can form adduct with amino acids and DNA. These compounds 
include several reactive a, f3-unsaturated aldehydes such as malondialdehyde (MDA) (Bartsch 
et al., 1999). They are strong electrophiles and can bind to the sulfhydryl groups and cysteine 
residues of proteins and DNA bases, showing both genotoxic and mutagenic actions (Luczaj et 
al., 2003). Low levels of these compounds were suggested to inhibit the transition of cells from 
the GO phase to the G 1 phase, prolong the G 1 phase and slow the progression through the S 
phase by inhibiting the activity of DNA polymerases for DNA synthesis (Conklin, 2002 and Rex 
et al., 2002). The affected cells may repair such damage. However, extensive damage leads to 
apoptosis and cell death. 
Tablel.l Lipid peroxide products of oxidative stress (Adapted from Kenneth et al, 2002) 
Free Nonradicals Lipid Peroxidation Secondary Products 
Radicals Products 
Hydroxyl radical Hydrogen Peroxyl radical Malondialdehyde 
(HO") peroxide (H202) (ROO") 
Peroxide radical Singlet oxygen Alkoxyl radical (RO·) 4-Hydroxyalkenals 
(02•) eo2) 
It has been reported that tumour cells are highly susceptible to free radical-induced 
cytotoxicity because they have decreased activity of fatty acid desaturase enzymes, decreased 
antioxidant content and decreased capacity to generate free radicals and lipid peroxides due to 
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the lower amount of cytochrome P450, which normally can participate in the initiation of lipid 
peroxidation (Begin et al., 1986; Cheeseman et al., 1986 and Das 1990, 1999). Therefore, it is 
expected that tumour cells may be more sensitive than normal cells to the attack of ROS 
generated from PUFAs. In addition, compared with normal cells, tumour cells have a higher 
tendency to ingest excessive PUFAs from the environment for the membrane construction to 
meet their high proliferation and migration. Thus, tumour cells may have more potential than 
normal cells to be targeted by ROS from PUFAs. 
1.1.3.3 Metabolism pathways of ro-6 and ro-3 PUFAs 
Substantial experimental evidence suggests that co-6 PUFAs enhance the risks of cancer 
development, while increased intake of co-3 PUFAs has inhibitory effects. Such a difference is 
likely due to the different metabolic pathways and metabolites of co-6 PUFAs vs. co-3 PUFAs as 
shown in Figure 1.2. co-6 PUFAs promote tumorigenesis and tumour cell proliferation directly 
and indirectly via increased synthesis of eicosanoids, the COX- and LOX-catalyzed products of 
AA (Noguchi et al., 1995). COX, which has two isoforms, COX-1 and COX-2, is a key enzyme 
responsible for the oxidation of AA to PGs. COX-1 enzyme is expressed constitutively in most 
cells and tissues, and stays constant under either physiological or pathological conditions to 
control the synthesis of PGs primarily involved in the regulation of homeostatic functions. In 
contrast, COX-2 is absent in normal cells but highly inducible under the stimulation by 
inflammatory, tumour promoters, cytokines and growth factors, resulting in enhanced PGs 
release (Bakhle et al., 1996 and Smith et al., 2000). The PGs produced from COX-catalyzed 
pathways possess a broad spectrum of biological activities. They primarily mediate pain and 
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inflammation but also favour tumorigenesis. The production of PGs is controlled in most 
normal tissues but tumour cells or the pathological tissue may produce larger amounts of PGs 
and eicosanoids than their normal counterparts, as it has been found that the levels of COX-2 
and PGs are more abundant in cancers than those in normal tissues from which the cancers arise, 
influencing the carcinogenic process (Spector and Bums, 1987). The PGs and other eicosanoids 
generated in tumour cells can act as tumour promoters, stimulate tumour growth or influence 
tumour migration and the metastatic potential. In human breast cancers and animal models, for 
example, it has been determined that COX-2 up-regulation and elevated PGE2 levels are 
involved in breast cancer growth and invasion as COX-induced PGs enhance estrogen synthesis 
in mammary tissue thereby stimulating growth in hormone dependent tumours (Tapiero et al., 
2002). 
In the metabolic pathway of ro-6 PUFAs, AA is the precursor of PGs and can be converted to 
2-series of PGs by COX-2 enzymes. The 2-series of PGs include PGH2, a common precursor for 
the biosynthesis of other 2-series PGs such as PGD2, PGE2, PGF2a, PGh, and thromboxane A2 
(TXA2). Eicosanoids such as PGI2 and TXA2 are important in tumour metastasis. PGh is 
synthesized primarily by vascular endothelial cells and inhibits platelet activation and 
aggregation, while TXA2, a product of COX from PGH2 in platelets, has opposing actions to 
PGI2, which is to promote platelet aggregation. They are involved in tumour angiogenesis by 
affecting the tumour cell-vascular endothelial cell and tumour cell-platelet interactions and 
tumour vascular formation. 
The 2-series of PGs and 4-series of LTs produced from LOX-pathway can also stimulate the 
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growth of malignant cells by suppressing host immunity as immunosuppressive and mutagenic 
substances (Das, 1990 and Noguchi et al., 1995). PGE2 can suppress the production of TNF-a, 
IL-l and IL-6 by monocytes and macrophages (Stulnig, 2003), while PGF2a is required for the 
invasive and metastatic activity of tumour cells (Reich et al., 1989). Therefore, it is thought that 
by suppressing the host immune response, eicosanoid products produced from AA help tumours 
avoiding immunologic inhibition and promote tumour initiation, division, proliferation, tissue 
invasion and metastatic spread. 
However, co-3 PUFAs can interfere with AA to produce certain eicosanoids and lead to less 
effective generation of these messenger molecules. Compared with co-6 PUFAs, co-3 PUFAs 
have a greater affinity for desaturase and elongase enzymes (Rose et al., 1999). Incorporation of 
co-3 PUFAs can inhibit early steps in the long-chain fatty acid biosynthesis by competing for the 
enzymes necessary for desaturation and elongation, causing the depletion of co-6 PUFAs 
including AA. In addition, as shown in Figure 1.2, both EPA and AA are the precursors of PGs 
in the eicosanoid metabolic pathway. EPA can compete with AA as the substrate for eicosanoid 
metabolism thereby blocking the AA metabolic pathway, giving rise to the 3-series of PGs with 
3 double bonds and 5-series LTs with 5 double bonds, which exert less biological activities in 
comparison to AA-derived eicosanoids (Koller et al., 2003), leading to a decline in the 
conversion to 2-series PGs and 4-series LTs which promote tumour origin, growth and 
metastasis. Thus, co-3 PUFAs may offset the effect of co-6 PUFAs on cancer cells. 
In conclusion, PUFAs may play their roles on tumour cells by affecting the composition of 
the cell membrane, creating lipid peroxide products and producing eicosanoids through their 
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metabolic pathways. 
1.2 Apoptosis 
1.2.1 Necrosis and apoptosis 
There are two distinct modes of cell death, necrosis and apoptosis. Necrosis ("accidental" 
cell death) is a pathological process and a result of acute cellular dysfunction which occurs 
when cells respond to a serious physical or chemical insult. It is progressive and results in 
irreversible damage and complete degradation of affected cells. Morphologically, necrosis is 
characterized by a dramatic increase in cell volume and rupture of the plasma membrane, with 
spilling of the cellular contents into the intracellular milieu. The release of the contents of 
necrotic cells can cause further tissue damage by affecting neighbouring cells, resulting in 
extensive inflammation response (Chandra et al., 2000). 
However, apoptosis ("normal" or "programmed" cell death) affects scattered single cells 
rather than tracts of contiguous cells. It is a spontaneous physiological process by which 
unwanted or useless cells are eliminated during development and other normal biological 
processes. Apoptosis is most often found during normal cell turnover and tissue homeostasis, 
embryogenesis, induction and maintenance of immune tolerance, development of the nervous 
system and endocrine-dependent tissue atrophy. As a complementary but opposite role to 
mitosis to keep the balance between cell production and loss, apoptosis regulates cell population 
by controlling cell deletion under both physiological and pathological conditions (Kerr et al., 
1972). 
The morphological changes occurring in cells upon apoptosis include cell membrane 
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alteration, cell shrinkage, nuclear condensation with the chromatin forming clumps that gather 
adjacent to the nuclear membrane, and nuclear fragmentation together with mono- and 
oligonucleosomal fragments of DNA breaks with 180-200 base pairs, as well as some 
apoptosis-related protein expression changes. During apoptosis, cytoplasm condenses, causing 
contraction of the cell, loss of volume and adhesion to surrounding cells. The cell surface then 
becomes irregular with numerous surface protrusions that eventually round up and break off as 
membrane-bound apoptotic bodies (apoptotic bodies), in which the integrity of various 
subcellular organelles is initially maintained. In biological systems, the apoptotic bodies are 
recognized, engulfed and digested by macrophages or phagocytosed by adjacent epithelial cells 
so no inflammatory response is elicited. Since the fragments of apoptotic cells are disposed by 
nearby intact cells, apoptosis is economical in terms of re-utilization of cell components (Kerr et 
al., 1972 and Wyllie, et al., 1980). Figure 1.3 shows the morphological features associated with 
necrosis and apoptosis. Table 1.2 summarizes the characteristics of necrosis and apoptosis. 
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Figure 1.3 Schematic diagram of morphological changes associated with necrosis and apoptosis 
(Adapted from http:/ /www.roche-applied-science.com) 
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Table 1.2 Differential features of necrosis and apoptosis 
(Adapted from http:/ /www.roche-applied-science.com) 
Necrosis Apoptosis 
Morphological features 
Loss of membrane integrity Membrane blebbing, no loss of integrity 
Begins with swelling of cytoplasm and Aggregation of chromatin at the nuclear 
mitochondria 
Ends with total cell lysis 
No vesicle formation, complete lysis 
Disintegration (swelling) of organelles 
membrane 
Begins with shrinking of cytoplasm and 
condensation of nucleus 
Ends with fragmentation of cell into smaller 
bodies 
Formation of membrane bound vesicles 
(apoptotic bodies) 
Mitochondria become leaky due to pore 
formation involving proteins of the Bcl-2 
family 
Biochemical features 
No energy requirement Tightly regulated process involving 
Random digestion of DNA 
activation and enzymatic steps 
Energy (ATP)-dependent 
Non-random mono- and oligonucleosomal 
length fragmentation of DNA 
Release of various factors (cytochrome C, 
AIF) into cytoplasm by mitochondria 
Activation of caspase cascade 
Alteration in membrane asymmetry (i.e., 
translocation of phosphatidylserine from 
cytoplasmic to the extracellular side of the 
membrane) 
Physiological features 
Affects groups of contiguous cells Affects individual cells 
Evoked by non-physiological disturbance Induced by physiological stimuli (lack of 
(complement attack, lytic viruses, 
hypothermia and metabolic poisons) 
Phagocytosis by macrophages 
Significant inflammatory response 
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growth factors, changes in hormonal 
environment) 
Phagocytosis by adjacent cells or 
macrophages 
No inflammatory response 
1.2.2 Cascade of apoptosis 
Unlike necrosis, apoptosis is complicated but precisely ordered for self-destruction rather 
than degeneration. It is a complex set of multi-step, multi-branched pathways with many 
checkpoints and balances. The whole process requires energy, protein synthesis and activation 
of series of subcellular components and factors for its execution. It can be triggered by a variety 
of physiological and chemical stimulation either from intracellular or extracellular 
environments, which initiate one or several distinct cross linking pathways (Figure 1.4). 
Intracellular triggers include DNA damage, telomere malfunction and inappropriate 
proliferative signals produced by oncogenic mutation. Extracellular triggers include chemical 
and radiation stimulation, growth factor depletion, hypoxia and loss of cell matrix. The 
activation pathways are dependent on the cell types and stimulation, but the general apoptotic 
cascade manifests itself in two major execution downstream pathways of the initiating signals: 
the caspase (cysteinyl-aspartate specific proteases, which dismantle cells by cleaving a subset of 
cellular proteins after aspartic acid residues) pathway and the organelle dysfunction. The 
caspase pathway is involved with many proteolytic enzymes subdivided into classes which 
initiate the process, propagate and amplify the signals. This pro-apoptotic machinery interacts 
with cellular survival mechanisms at different levels, including related proteins such as p53 
protein and Bcl-2 family members. The organelle pathway is best characterized by 
mitochondrial dysfunction. 
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Figure 1.4 Schematic illustrations of various phases of apoptosis 
(Adapted from Grosset al., 1999) 
1.2.3 Some important apoptotic markers 
1.2.3.1 p53 protein 
Preserving genomic integrity by the repair or removal of damaged DNA is essential for cell 
survival as the persistence of genomic damage could potentially lead to neoplasia. p53 protein 
acts as a tumour suppressor involved in damage recognition and DNA repair. It can induce cell 
growth arrest, senescence, or apoptosis in response to a variety of cellular stresses including 
exposure to DNA damage, hypoxia, nucleotide depletion and oncogene activation (Sionov et al., 
1999). p53 protein performs as a checkpoint protein during the 01 and 02 phases of the cell 
cycle to prevent cells with damaged genomes from undergoing DNA replication and mitosis 
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(Sionov et al., 1999 and Haupt et al., 2003). When cells encounter DNA damage such as 
double-strand breaks, the level of p53 increases rapidly and induces G 1 arrest, stopping DNA 
replication, which allows DNA repair to take place. If this is not possible or DNA repair 
mechanisms fail, then p53 triggers apoptosis to eliminate damaged cells permanently. This 
growth inhibitory activity prevents the proliferation of cells with damaged DNA or with a 
potential neoplastic transformation. 
p53 protein induces extrinsic and intrinsic apoptotic signalling pathways that lead to the 
activation of the caspases to execute apoptosis. The extrinsic pathway involves engagement of 
particular death receptors that belong to the tumour necrosis factor receptor family. Through the 
formation of the death-inducing-signalling-complex, this pathway leads to a cascade of 
activation of caspases, which in turn induce apoptosis. The intrinsic pathway is triggered in 
response to DNA damage and is associated with mitochondrial depolarization, the release of 
cytochrome c and apoptotic protease-activating factor-1 (APAF-1) from mitochondria into 
cytoplasm, and the shift of balance in the Bcl-2 family towards to the pro-apoptotic members, 
promoting the formation of the apoptosome, and consequently caspase-mediated apoptosis 
(Haupt et al., 2003). 
1.2.3.2 Bcl-2 protein family 
The Bcl-2 protein family is another crucial group of proteins related to apoptosis. The first 
found member, Bcl-2 oncogene, was discovered present at the interchromosomal breakpoint of 
the t(14;18), the molecular hallmark of follicular B cell lymphoma/leukemia-2 (Chao et al., 
1998). According to the effect on apoptosis, the Bcl-2 protein family is divided into 
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pro-apoptotic proteins (agonist) such as Bax, Bak, Bcl-Xs, Bad and anti-apoptotic proteins 
(antagonist) including Bcl-2 and Bel-XL (Table 1.3). 
Table 1.3 Bcl-2 family proteins 
Anti-apoptotic 
Bcl-2 
Bcl-XL 
Bcl-w 
Mcl-1 
A1 
Pro-apoptotic 
Bcl-Xs 
Bax 
Bak 
Bid 
Bad 
Bcl-2 family proteins execute their functions by dimerizing with homologous proteins, 
associating with non-homologous proteins, and forming ion channels and pores or integral 
membrane proteins to affect the organelles where they reside (Grosset al., 1999). Bcl-2 family 
members possess up to four conserved regions, namely Bcl-2 homology (BH) domains. The BH 
domains that individual proteins have in common appear to be crucial in the ability of these 
proteins to bind with each other and enhance or attenuate the action of the others. All Bcl-2 
family proteins share at least one of BH domains that are important for homodimer or 
heterodimer formation. For example, many of the anti-apoptotic members display sequence 
conservation in all four domains, whereas the pro-apoptotic molecules usually lack BH4 but 
preserve BH3 domain, which is critical for induction of apoptosis (Grosset al., 1999). Evidence 
suggests that by binding at the BH domains, Bax: Bax homodimers tend to promote apoptosis 
and Bcl-2: Bcl-2 homodimers can act to anti-apoptosis; however, Bax can form heterodimers 
with Bcl-2 or Bcl-XL to abolish their anti-apoptotic activity. Therefore, the dominant dimerized 
molecules of Bcl-2 protein members determine cell fate for survival or apoptosis (Sheikh et al., 
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2000). 
Some of the Bcl-2 family proteins can be regulated by p53 protein. Pro-apoptotic protein 
Bax, for example, is a known target of p53 protein and can be up-regulated by p53 in some cell 
types by y-radiation, chemotherapeutic drugs and other forms of genotoxic stress (Zhan et al., 
1994), while anti-apoptotic protein Bcl-2 was reported to be able to be down-regulated by p53 
(Miyashita et al., 1995 and Haldar et al., 1994). Thus, induction of Bax expression and 
down-regulation of Bcl-2 after p53 activation leads to an altered Bcl-2/Bax ratio which may be 
important in inducing apoptosis. On the other hand, Bcl-XL, an anti-apoptotic protein, is 
reported to be able to inhibit p53-mediated apoptosis in certain breast cancers (Bronchud et al., 
2000), suggesting that Bcl-2 family proteins can also regulate apoptosis by influencing p53 
protein. 
Bcl-2 family members may insert into intracellular membranes and function as ion channels. 
Anti-apoptotic Bcl-2 family members are integral membrane proteins in the mitochondria, 
endoplasmic reticulum and nuclear membrane (Rose et al., 1993). However, a substantial 
fraction of such pro-apoptotic members as Bax localizes in cytosol or cytoskeleton. Following a 
death signal, activation of the cytosolic pro-apoptotic members appears to involve subcellular 
translocation and dimerization. They target and integrate into membranes, especially the 
mitochondrial outer membrane, where they become integral membrane proteins and cross-link 
dimers (Gross et al., 1998 and Gross et al., 1999). Bax homodimers and Bax: Bcl-2 
heterodimers can form ion-conductive pores in mitochondrial membrane. They control the 
release of apoptotic factors from mitochondrial intermembrane into cytoplasm by the regulation 
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of mitochondrial membrane permeability. Under apoptotic stimuli, the mitochondrial 
transmembrane potential (~'I'm) is decreased and the pore is open. The opening pore allows the 
intra-mitochondrial cytochtome c, apoptosis-inducing factors (AIF) and some caspases to be 
released into the cytosol. Once cytochrome c reaches the cytoplasm, it binds to apoptotic 
protease-activating factor-! (APAF-1), which is a cytoplasmic protein, to produce an 
ATP-dependent complex to recruit and activate the caspase cascade; the post-mitochondrial 
apoptotic pathway thereby is activated (Haupt et al., 2003) (Figure 1.5). 
Bcl-2 family proteins can also act as a checkpoint at the upstream of caspases. 
Pro-apoptotic members such as Bax and Bad connect survival signals, while anti-apoptotic 
members of Bcl-2 family can shut off the apoptotic signal transduction pathway that is located 
in the upstream of caspase activation (Chao et al., 1998). 
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Figure 1.5 Schematic model of apoptosis pathway (Adapted from Grosset al., 1999) 
1.2.3.3 Mitochondria and cytochrome c 
Mitochondria are cellular powerhouses and respiration organelles. They play a decisive 
role in apoptotic pathway. The organelle apoptotic pathway, which is mitochondrial dysfunction 
under apoptosis, is characterized by a loss of membrane barrier functions including opening of 
the permeability transition pore (PTP), collapse of the membrane potential, and a release of 
various classes of molecules from the intermembrane space via the outer mitochondrial 
membrane. The PTP is a large conductance pore that is permeable to solutes with molecular 
mass of around 1500 Daltons. The molecules released upon opening the PTP include at least: 1) 
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cytochrome c, which participates in the activation of caspases; 2) procaspases, in particular 
procaspase-2, -3, and -9, which may facilitate the activation upon release from the 
intermembrane space; 3) apoptosis-inducing factor, a flavoprotein which induces large scale of 
chromatin fragmentation (Jacobson et al., 2002). As a result of the release of these factors, the 
downstream caspases are activated and come into action, leading to the biochemical and 
morphological hallmarks of apoptosis. Opening the PTP also induces loss of ion gradient and 
mitochondrial depolarization, causing influx of water into mitochondria and swelling of the 
mitochondria (Grosset al., 1999). Expanding of the matrix space eventually results in organelle 
rupture and consequent elimination by apoptosis. 
Cytochrome c normally resides between the inner and outer mitochondrial membranes and 
functions as a part of the respiratory chain in mitochondria. When apoptosis happens, apoptotic 
signals promote the translocation of Bax from cytosol to the outer layer of mitochondrial 
membrane, forming the channels to allow cytochrome c to escape into the cytoplasm. When 
released into the cytosol, cytochrome c becomes a critical component of the apoptosis execution 
machinery, where it activates caspases. Cytochrome c needs another cytosolic factor to initiate 
apoptosis. This factor is designated APAF-1. Cytochrome c combines with APAF-1 in 
conjunction with ATP to activate pro-caspase-9 to caspase-9, which then activates caspase-3 and 
-7. Caspase-3 can activate caspase-2 and -6, while caspase-6 can activate caspase-8 and -10 
(Palmer et al., 2000). In tum, these caspases cleave and activate a variety of substrates and key 
cellular regulators to enable collapse of cells and give rise to characteristic morphological 
changes of apoptosis such as membrane bleb, chromatin condensation, and DNA fragmentation. 
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Moreover, caspase-3 can activate caspase-9 again, and provides a positive feedback loop to 
some of the Bcl-2 proteins, for example, pro-apoptotic protein Bid, leading to the amplification 
of apoptotic signals (Figure 1.6). 
Cyt c/Apaf-1 
I cas-9 
~ ...-.---
I cas-3 cas-7 
/+ 
,----c-as---6---,1 I cas-2 
"" cas-8 I 
L___ca_s_-1_o _ ____. ~ 
I Apoptosis 
Figure 1.6 Order of caspase activation events downstream of Apaf-1/cytochrome c complex 
(Adapted from Palmer et al., 2000) 
1.2.4 Apoptosis in cancers 
The size of a cell population depends on the balance between cell production and cell loss. 
Apoptosis is an important mode of controlled cell death, which contributes to the regulation of 
cell populations. Cancers occur through unregulated cell division, enhanced proliferation, 
diminished cell turnover and abnormal apoptotic machinery. Loss of apoptosis can impact on 
carcinogenic processes to extend tumour life span and resistance to chemo- and radiotherapy. 
One way to avoid apoptosis by cancer cells is through oncogenic mutations, leading to a change 
of expression of apoptotic proteins. 
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1.2.4.1 Change of the expression of Bcl-2 family members in cancers 
Overexpression of anti-apoptotic Bcl-2 family members has been widely observed in 
human tumour cells (Reed, 1998). It is believed to be associated with increased resistance of the 
cancers to treatments, and results in a poorer prognosis. These anti-apoptotic proteins appear to 
prolong the survival of cells and allow additional mutation or genetic changes so the propensity 
of cancer development is increased. They can also exert their effects by blocking cytochrome c 
release from mitochondria and consequently to inhibit the activation of caspases cascade. In 
addition, abnormally high Bcl-2 expression in cancers has been shown ultimate resistance of 
cells to diverse apoptosis stimulation, including chemotherapeutic drugs and radiation, growth 
factor deprivation, hypoxia, loss of cell attachment to extracellular matrix (relevance to tumour 
metastasis) and lysis by cytolytic T cells (Reed et al., 1996). 
1.2.4.2 Dysfunction of p53 and lack of caspase-3 in cancers 
The mutated p53 gene has been found in over 50% of tumours. It has been estimated that 
the vast majority of tumours have a disruption in the p53 pathway either by mutation of p53 or 
inhibition of p53 function (Bums et al., 1999 and Haupt et al., 2003). Tumours with mutated 
p53 can be more anaplastic, metastatic and aggressive, and have a higher rate of proliferation 
than those with wild-type p53 (Brown et al., 1999). They can survive from those stimuli that 
normally activate wild-type p53 to promote apoptosis. 
The expression of caspase-3, the central protein in the execution of apoptosis, has been 
found altered in most breast cancer cases as well. Approximately 75% of the breast cancer tissue 
samples lack in the caspase-3 transcript and expression, and the remaining samples show 
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substantial decrease of the caspase-3 expression (Devarajan et al., 2002). For example, 
resistance to apoptotic stimuli and decreased sensitivity to such chemotherapeutic agents as 
cisplatin, doxorubicin and etoposide have been reported in MCF-7 human breast cancer cells 
that lack the expression of caspase-3 (Janicke et al., 1998). However, reconstitution with 
caspase-3 rendered MCF-7 cells sensitive to these stimuli, suggesting that the loss of caspase-3 
expression represent an important mechanism of cell survival and chemo-resistance by breast 
cancer cells (Poznak et al., 2002 and Devarajan et al., 2002). 
Since genetic alteration that disables the apoptotic pathway is presented in carcinoma and 
produces multi-drug resistance, restoring and activating apoptosis should be a critical strategy in 
cancer treatments. 
1.3 Breast cancer 
1.3.1 Breast cancer and hormone 
Breast cancer is the most common cancer in North American society and is the second cause 
of cancer-related death in women (Poznak et al., 2002). It is characterized and affected by 
female sex steroid hormones, namely estrogen and progesterone. The biological activities of 
steroid hormones are mediated by acting with their specific receptor proteins. With hormone 
binding, the ligand-receptor complex acquires high affinity for specific chromosomal 
binding-sites and interacts to modulate transcription of specific genes to regulate the secretion 
of proteins with growth-factor-like activities and the specific protein biosynthesis such as 
increased progesterone receptor production. The proteins with growth-factor-like activities 
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include the epidermal growth factor (EGF), transforming growth factor-a (TGF-a) and other 
TGF-a-like proteins, insulin-like growth factors (IGF) and fibroblast growth factors, which can 
trigger cell division (Dickson et al., 1986; Berkenstam et al., 1989 and Leonessa et al., 1992). 
There are two major phenotypes of breast cancer, hormone dependent and hormone 
independent breast cancer. In hormone dependent breast cancer, the tumour cells express high 
levels of estrogen receptors (ER) and/or progesterone receptors (PR), and have a low metastatic 
potential. In contrast, hormone independent breast cancer lacks hormone receptors (ER- and 
PR-), and hormones are not necessarily required for tumour growth. They do not respond to 
hormonal stimulation since they frequently exhibit a high level of constitution growth factor 
expression which is not regulated by hormones, e.g., high levels of EGF receptors (Leonessa et 
al., 1992). These kinds of breast cancers are usually found in late stage breast cancers because 
they tend to be more aggressive and invasive, with higher proliferation. They are generally more 
difficult to be treated due to the altered expression of growth factor receptors and elevated 
expression of enzymes of drug metabolism. 
1.3.2 Factors influencing breast cancer occurrence 
Studies suggest that there are many risk factors responsible for the increased likelihood of 
developing breast cancer, including diets, family inheritance, early menarche, late menopause, 
and hormone replacement therapy (Gerber et al., 2003). For example, early menarche and late 
menopause would increase the exposure time of breast tissue to estrogenic stimulation, resulting 
in increased breast cancer occurrence, while early first full-term pregnancy and breast feeding 
appear to have some protective effects against breast cancer as pregnancy and prolonged 
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lactation involve the differentiation of breast epithelium, and reduce the term and level of 
estrogenic stimulation (Leonessa et al., 1992). 
Obesity in women is believed to be a risk factor for breast cancer as obesity is related to 
estrogen production and metabolism (Kirschner et al., 1982). Obesity results in abnormal 
hormone production. In obese individuals, the estrogen levels are elevated as a result of the 
increased production of estrone and estradiol from their precursors (androstenedione to estrone 
and testosterone to estradiol) by the estrogen-forming enzymes. The increased estrone and 
estradiol accumulate in the fat cells because adipose tissue is the major site of conversion 
(Kirschner et al., 1982 and Siiteri, 1987). In addition, since only the free or unbound fraction of 
steroid hormones in plasma is biologically active, whereas some proteins which have high 
affinity with estrogen such as sex-hormone-binding globulin and high-density lipoprotein are 
depressed in obese subjects, the greater amount of free estrogen than normal in obese 
individuals is therefore available to target tissues from the circulation (Siiteri, 1987). 
Hyperestrogenism from obesity leads to excessive chronic stimulation of estrogen responsive 
target organs leading to hyperplasia and subsequently neoplasia (Kirschner et al., 1982). 
Since the environment is the foundation for all health and disease, and food is the most 
important part taken from the environment, extensive attention must be paid to diet and lifestyle. 
Studies show that the type and the amount of dietary fats consumed are implicated in the breast 
cancer aetiology. It has been reported that the population suffering from cancers is very low in 
Greenland Eskimo populations whose traditional diet contains relatively substantial amounts of 
unsaturated fatty acids and low fat compared to reference populations in the West (Byers, 1996). 
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Japanese consume diets high in long chain co-3 PUFAs as well; however, Japanese migrants to 
the U.S. who adopt an American diet typically experience rapid increases in breast cancer 
incidence compared to their counterparts in Japan (Gerber et al., 2003). This indicates that diet 
and lifestyle dominate over genetic predisposition towards breast cancer occurrence. 
Epidemiological and animal studies suggest that the present western dietary supply of fatty 
acids is greater than a 10:1 ratio of co-6 to co-3 PUFAs instead of 1:1 prior to industrialised 
society, causing a deficiency of co-3 PUFAs, a high proportion of calories and high fat 
consumption all of which are associated with an increased incidence and growth of breast 
cancer (Horrocks et al., 1999, Simopoulos, 2002 and Gerber et al., 2003). Therefore, nutrition 
and diet are important factors impacting breast cancer occurrence. 
1.3.3 Treatments of breast cancer 
As for treatments for breast cancer, the first choice is surgery. If the breast cancer has not 
undergone metastasis, the surgical approach is very successful (Buzdar, 2001). In addition to 
surgery, endocrine therapy, chemotherapy and radiotherapy are other treatment approaches. 
Whether a tumour is hormone receptor-positive or negative is served as a useful predictive 
marker and treatment target in the clinic. Hormone receptor-positive tumours such as ER+ 
and/or PR+ are often treated with endocrine therapies. For example, tamoxifen, an estrogen 
antagonist, has been used as the conventional first-line endocrine therapy for breast cancers in 
women with ER+ diseases. It competes with estrogen for ERs, thereby blocking them and 
interrupting estrogenic action on tumours (Mamounas et al., 2001). However, tumours that 
initially respond to one type of endocrine therapy often become refractory to that therapy. Thus, 
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a sequential endocrine therapy with second-, third- and fourth-line endocrine therapies using 
different types of estrogen antagonist or androgen is offered as resistance develops and disease 
progresses. If all endocrine options have been exhausted, or patients present receptor-negative 
diseases, radio- or chemotherapy will be considered. 
Today, breast cancer is usually considered as a systemic disease from its earliest stages 
because micrometastases may be present at the time of diagnosis due to the rich breast 
parenchyma, mammary ducts and breast lymphatics. Hence, systemic hormonal therapy and 
chemotherapy as adjuvant treatments have been used and have achieved significant therapeutic 
goals to increase survival (Buzdar, 2001). 
1.4 Paclitaxel 
1.4.1 Mechanisms of anti-tumour activity of paclitaxel 
Paclitaxel (Taxol) (Figure 1.7) is one of the most active first-line broad-spectrum anti-cancer 
drugs, and is particularly effective against primary epithelial breast cancer, ovarian carcinoma, 
colon, head and neck, and non-small cell lung cancer. It was isolated from the bark of Pacific 
Yew (Taxus brevifolia) in the early 1960s (Singla et al., 2002). Paclitaxel inhibits cell 
proliferation by promoting the polymerization of tubulin and inducing a sustained mitotic block 
in the late 02 or M phases of the cell cycle. The tubulin/microtubule system plays a significant 
role in mitosis, intracellular transport, cell motility and maintenance of cell shape. The spindle 
microtubule formed in the presence of paclitaxel is extraordinarily stable and dysfunctional, 
thereby preventing chromosome segregation and subsequent cellular division, causing cell 
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death by disrupting the normal tubule dynamics required for cell division and vital interphase 
process (Rowinsky et al., 1997 and Singla et al., 2002). 
0 
0 
Paclitaxel I \--0 
Figure 1.7 Structure of paclitaxel (Adapted from Singla et al., 2002) 
In addition to the disruptive action of cell mitosis by paclitaxel, the induction of apoptosis 
is another mechanism for the antineoplastic effects of paclitaxel. Several studies have reported 
that paclitaxel induces apoptosis in certain cancer cell types as breast cancer cells, leukemia 
cells and lung cancer cells by causing the production of cytokines and interleukin-1, Bcl-2 
phophorylation, disruption of the balance between the dimerization of Bcl-2 and Bax protein, 
and the release of cytochrome c from mitochondria followed by activation of a caspase-9 
cascade (Huang et al., 1997; Torres, et al., 1998; Yeung et al., 1999 and Blajeski et al., 1999). 
The mode of action of paclitaxel is multistep, concentration- and cell type-dependent. In breast 
cancer cell lines, the paclitaxel concentrations that induced apoptosis range from 5- 1000 nM 
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(Rowinsky 1997, Yeung et al., 1999 and Charles et al., 2001), which are remarkably lower than 
the concentrations that cause non-specific necrotic cell death in vitro and also significantly 
below the attainable effective serum levels in patients (Saunders, 1997). It has been reported 
that when breast cancer cell lines, including hormone dependent MCF-7 cells and hormone 
independent MDA-MB-231 and MDA-MB-468 cells, were treated with paclitaxel at 2:: 10 nM 
for 3-24 hrs, cell growth inhibition, high molecular weight and oligonucleosomal DNA 
fragmentation and apoptosis-associated morphological changes were observed (McCloskey et 
al.,1996; Saunders et al., 1996; Huang et al., 1997 and Rowinsky et al., 1998). Various 
apoptotic machineries have been reported to be involved in response to paclitaxel in breast 
cancers, including p53 pathway, phosphorylation of Bcl-2, mitogen-activated protein kinases 
cascade, ceramide generation and mediation of some gene expression (Young et al., 1999; 
Bacus et al., 2001; Charles et al., 2001 and Blajeski et al., 2001). 
1.4.2 Formulations of paclitaxel 
Given the fact that paclitaxel undergoes extensive metabolism in the liver following oral 
administration, it is best administrated intravenously. For metastatic breast cancer, paclitaxel is 
usually given via infusion at 135-175 mg/m2 every one to three weeks (Poznak et al., 2002 and 
Singla et al., 2002). Although paclitaxel is a promising anti-tumour agent, its poor water 
solubility is its greatest disadvantage. The current formulation for infusion employs a 
non-aqueous vehicle composed of Cremophor EL, a non-ionic surfactant, and ethanol at 1:1 
ratio (v/v) which is diluted in normal saline or 5% dextrose solution prior to administration 
(Singla et al., 2002). However, problems employing this vehicle have been reported. Firstly, 
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Cremophor EL causes histamine release and thereby leads to allergic reactions in patients. Fatal 
hypersensitivity reactions are the most prevalent. Therefore, histamine antagonists and 
immunosuppressant have to be given to patients prior to the paclitaxel treatment. Secondly, 
Cremophor EL is also found to be physically incompatible with the intravenous infusion sets 
(Singla et al., 2002). It can result in the leaching of diethylhexylphtalate from PVC infusion sets, 
causing pain to patients. In practice, plasticizer-free containers or bags have to be used. Thirdly, 
paclitaxel can slowly precipitate out of the diluted solution during infusion. Hence, an in-line 
filter is recommended to remove the particles during intravenous administration, which causes 
inconvenience to medical staff. Moreover, the high toxicity of paclitaxel which includes 
neurotoxicity, myalgias/ arthralgias, bone marrow suppression (principally neutropenia), 
myocardial ischemia and atrial arrhythmias, complete alopecia, and hypersensitivity reactions 
also raises much clinical concern (Poznak et al., 2002 and Markman, 2003). 
Due to these factors there is a need to develop novel formulations of paclitaxel with 
improved aqueous solubility and at the same time decreased side effects. Various strategies have 
been investigated including the preparation of emulsions, liposomes, microspheres, 
nanocapsules and soluble semi-synthetic paclitaxel derivatives to avoid the use of Cremophor 
EL (Singla et al., 2002). However, no apparent success has been achieved. 
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Chapter 2 Objective 
ro-3 PUFAs have been reported to be beneficial in treating cancers. The objective of this 
study was to investigate the effects of seal oil rich in ro-3 PUFAs on the cytotoxicity and 
apoptosis caused by paclitaxel in breast cancer cell lines. 
Breast cancers with different phenotypes, MCF-7, a hormone dependent cell line, and 
MDA-MB-231, a hormone independent cell line, were chosen as in vitro models. In the first 
step, cells were treated with varying concentrations of seal oil for different time intervals and 
the cytotoxicity was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. Since MTT assay showed that seal oil was toxic to both cell lines and 
induced cell death, optional conditions for apoptosis induction by seal oil were then determined. 
Following incubation of cells with seal oil, paclitaxel alone and paclitaxel in combination with 
seal oil, respectively, cell viability was examined by MTT assay and apoptotic characteristics 
presented at different stages were investigated using various assays including Hoechst staining, 
TUNEL assay and Annexin-V-FLUOS staining. The expression of two apoptotic marker 
proteins, p53 and Bcl-2, was measured by Western blotting assay. To further illustrate the 
mechanisms of cytotoxicity and apoptosis induced by seal oil, the production of intracellular 
lipid peroxide products was examined, as the highly unsaturated PUFAs derived from seal oil 
were considered to be susceptible to oxidative stress. Gas chromatography was used to reveal 
changes of lipid composition in cells following seal oil treatments, to determine if there was a 
relationship between the changes with the lipid peroxide production. 
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In comparison to seal oil, lntralipid®, which is a soybean oil emulsion containing ru-6 
PUFAs, was also studied for its cytotoxicity and apoptosis induction. 
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Chapter 3 Materials and Methods 
3.1 Materials 
Human breast cancer cell lines, MCF-7 and MDA-MB-231, were kindly provided by Dr. 
Alan Pater, Division of Basic Medical Sciences, Faculty of Medicine, Memorial University of 
Newfoundland, St. John's, NL, Canada. 
Dulbecco's modified Eagle's medium (DMEM) and 1X trypsin-ethylenediamine tetraacetic 
acid (trypsin-EDTA) were purchased from Sigma-Aldrich Canada Ltd. Fetal bovine serum (FBS 
HyClone®) and penicillin-streptomycin (Cellgro®) were provided by HyClone Laboratories, Inc. 
Paclitaxel was purchased from Shanghai Fudan Taxusal New Technology Corp., Shanghai, 
China. Harp seal oil was obtained from Caboto Seafoods Ltd., St.John's, NL, Canada and 20% 
Intralipid® was purchased from Baxter Corporation Toronto, Canada. 
VWR International supplied 25 cm2 and 75 cm2 cell culture flasks, 6- and 96-well cell culture 
plates and 8-well Lab-Tek chamber sliders. 
Hoechst 33342, MTT, tris-base, igepal CA-630, sodium azide, sodium dodecyl sulphate 
(SDS), deoxycholic acid sodium salt, phenylmethylsulfonyl fluoride (PMSF), aprotinin, 
acrylamide mix (29% of acrylamide and 1% N, N'- methylenebisacrylamide), ammonium 
persulphate, N, N, N ', N ' - tetramethylethylenediamine (TEMED), vitamin E, lecithin and 
hydroquinone were purchased from Sigma-Aldrich Ltd. Canada. Sigma was also the provider of 
optima grade dimethyl sulfoxide (DMSO), acetone, methanol, chloroform, hexane and carbon 
bisulfide (CSz). Hydrochloric acid, potassium chloride, sodium chloride, sodium phosphate, 
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potassium phosphate, glycine and Tween-20 were provided by Fisher Scientific Canada. 
PUFA-2 and PUFA-3 standards from Supelco, U.S.A. were kindly offered by Dr. Gene 
Herzberg, Department of Biochemistry, Faculty of Science, Memorial University of 
Newfoundland, St. John's, NL, Canada. 
Mounting medium for fluorescence (VectaShield®) was purchased from Vector Laboratories, 
Inc. and Roche Diagnostics provided In Situ Cell Death Detection Kit and Annexin-V-Fluorescein 
Staining Kit. 
Novocastra Laboratory was the provider of mouse anti-human monoclonal antibody (mAb) 
for p53 protein (specific for human p53 wild-type and mutant forms). Santa Cruz Biotechnology 
provided the mouse anti-human mAb for Bcl-2 protein. The mouse anti-human mAb for ~-actin 
protein was obtained from Sigma. The secondary antibody, anti-mouse Ig horseradish peroxidase 
linked whole antibody (from sheep) and chemiluminescence detection solutions were purchased 
from Amersham Biosciences UK Ltd. Electrophoresis apparatus and electrophoretic transfer 
apparatus for Western blotting assay were purchased from Bio-Rad Laboratories, Inc. 
Delsa-44 particle size analyzer was purchased from Beckman Coulter (Miami, FL, USA). 
Centra-CL 3-series ventilated centrifuge was purchased from Thermo IEC U.S.A. Microplate 
Reader (Bio-Rad Model 550) equipped with Manager 4.0 Bio-Rad software, bovine serum 
albumin (BSA) and DC protein assay kit were obtained from Bio-Rad Laboratories, Inc. and were 
used to analyze protein concentration. 
Olympus BX50 40x0.65 fluorescence microscope was used for morphological assessment. 
Thiobarbituric acid reactive substances (TBARS) assay kit was purchased from ZeptoMetrix Corp. 
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and Beckman DU-70 spectrophotometer was used for the analysis of lipid peroxide products. 
Hewlett Packard 5890 Series ll Gas Chromatograph was employed for the analysis of lipid 
composition. 
3.2 Methods 
3.2.1 Cell culture 
MCF-7 and MDA-MB-231 cells were maintained as monolayers in 75 cm2 flasks in DMEM 
containing 10% FBS and 1% penicillin-streptomycin, and routinely cultured at 37 °C in a 
humidified incubator with an atmosphere of 5% C02. 
Once cells grew to 80-90% confluence, they were subcultured. In order to subculture, the 
medium was removed and the monolayer was washed with approximately 10 mL of phosphate 
buffered saline (PBS, pH 7.4, 2.67 mM KCl, 1.47 mM KH2P04, 138 mM NaCl and 8.1 mM 
Na2HP04.7H20). The PBS was then removed and 3 mLof 1X trypsin-EDTA solution was added to 
each flask. The flasks were then placed back in the incubator for approximately 5 min. Once the 
majority of cells had detached from the flasks, approximately 7 mL of PBS was added to each flask 
and the cell suspension was transferred to a sterile 15 mL conical centrifuge tube. The cells were 
then precipitated by centrifuging at 3000 RPM for 5 min using a Thermo IEC tabletop centrifuge. 
Following centrifugation, the supernatant was carefully removed with disposable pipettes and the 
cell pellets were then re-suspended with DMEM and reseeded at 1:3 or 1:4 in each flask. Cells in 
the logarithmic phase of growth were used for all experiments. 
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3.2.2 Preparation of paclitaxel solutions, seal oil emulsions and soybean oil emulsions 
One hundred mM and 100 J..lM of paclitaxel solutions were prepared in DMSO and sterilized 
using a 0.2 J.lm Coming® syringe filter. In order to determine the IC50 value of paclitaxel, 100 mM 
of sterilized paclitaxel in DMSO was diluted with Dl\1EM to 400 J.lM, 100 J.lM, 25 J.lM, 6.25 J.lM, 
1.56 J.lM and 0.39 J.lM by serial dilution. The final DMSO concentration in all preparations was 
less than 0.5% (v/v), which was previously determined to be non-toxic to cells (Butt, 2004). To 
induce apoptosis, 100 nM paclitaxel solution was prepared by diluting the 100 J.lM paclitaxel with 
Dl\1EM prior to experiments. 
The 10% (w/v) seal oil emulsion containing 0.02% vitamin E, 1.2% lecithin and 2.5% 
glycerol was prepared using high pressure lipid extrusion method. The mean particle size of seal 
oil emulsion was determined by a Beckman Coulter Delsa-44 particle size analyzer (Miami, FL, 
USA) and was found to be in the range of 300±30 nm in diameter. 
Prior to each experiment, the 10% seal oil emulsion prepared above and 20% soybean oil 
derived from Intralipid® were diluted with Dl\1EM to 0.004%, 0.008%, 0.016% and 0.032% 
~.'3)Assessment of cytotoxicity by MTT assay 
The MTT assay was used for the examination of cytotoxicity. The method is based on the 
conversion of the yellow tetrazolium salt, MTT, to a coloured formazan product by mitochondrial 
dehydrogenase enzymes present only in the living and metabolically active cells (Sladowski et al., 
1993). The absorbance read through a spectrometer reflects the number of living cells. 
3.2.3.1 Cytotoxicity of seal oil in MCF-7 and MDA-MB-231 cells 
Cells were seeded at 0.5x105/100 J..tUwell in 96-well tissue culture plates and were incubated 
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at 37 °C in a 5% C02 humidified incubator for 24 h. The medium was then removed and cells were 
treated with medium containing 0.004%, 0.008%, 0.016% and 0.032% seal oil for 24, 48 and 72 h, 
respectively. In parallel, cells treated with fresh medium under the same conditions were used as 
control. After the desired incubation period, medium was removed and cells were washed twice 
with PBS. Cells were then incubated with 100 J..lL of MTT in PBS (0.5 mg/mL) at 37 °C for 4 h. 
Then, the supernatant was removed by aspiration and 100 J..lL of DMSO was added to each well to 
dissolve the formazan crystals formed. The plates were then agitated on a shaker at room 
temperature for 20 min to ensure that all crystals had been dissolved, and read in a Bio-Rad Model 
550 microplate reader at a measurement wavelength of 570 nm with a reference wavelength of 630 
nm. 
Data analysis was carried out using the Bio-Rad Microplate Manager® 4.0 program. The 
percentage of cell survival was calculated as: (mean absorbance of the treated well/ mean 
absorbance of the control well) x 100%. The experiments were repeated at least three times and the 
results were expressed as mean± standard deviation (SD). 
3.2.3.2 Cytotoxicity of paclitaxel in the absence and presence of seal oil in MCF-7 and 
MDA-MB-231 cells 
Cells were seeded at 0.5x105/100 J..tUwell in 96-well plates and were incubated at 37 °C in a 
5% C02 humidified incubator for 24 hrs. The medium was then removed and cells were treated 
with medium containing varying concentrations of paclitaxel (0.39 JlM, 1.56 JlM, 6.25 JlM, 25 JlM, 
100 JlM and 400 JlM) in the absence or presence of 0.016% seal oil for 24 h, respectively. Cells 
treated with fresh medium without drug under the same conditions were used as control. After 24 h, 
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medium was removed and cells were washed twice with PBS. Cells were then incubated with 100 
~L of MTI solution (0.5 mg/mL) at 37 °C for 4 h, following which the supernatant was aspirated 
and 100 ~L of DMSO was added to each well to dissolve the formazan crystals formed. Plates 
were then placed on a shaker and agitated at room temperature for 20 min to ensure that all crystals 
had been dissolved, and then read in a plate reader at a measurement wavelength of 570 run with a 
reference wavelength of 630 nm. 
The percentage of cell survival was obtained as previously described. A curve of the 
percentage of cell viability against the logarithmic concentrations of paclitaxel was obtained using 
SigmaPlot® 8.0 program. The paclitaxel concentration resulting in 50% of cell survival obtained 
from the curve was defined as the IC50 of paclitaxel. The experiments were repeated at least three 
times and the results were expressed as mean IC50 ± SD p.M. 
3.2.3.3 Cytotoxicity of soybean oil in MCF-7 and MDA-MB-231 cells 
Cells were seeded at 0.5x105/100 ~Uwell in 96-well tissue culture plates and were incubated 
at 37 °C in a 5% C02 humidified incubator for 24 hrs. The medium was then removed and cells 
were treated with medium containing 0.004%, 0.008%, 0.016% and 0.032% soybean oil for 24, 48 
and 72 h, respectively. Cells treated with fresh medium under the same conditions were used as 
control. After the desired incubation periods, cells were washed with PBS twice followed by 
incubation with 100 ~L of MTI solution (0.5 mg/mL) for 4 hat 37 °C. Then, the supernatant was 
aspirated and 100 ~LofDMSO was added to each well to dissolve the formazan crystals generated. 
The plates were then agitated on a shaker at room temperature for 20 min and read in a plate reader 
using a measurement wavelength of 570 nm with a reference wavelength of 630 run. 
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The percentage of cell survival was defined as previously described. The experiments were 
repeated at least three times and the results were expressed as mean ± SD. 
3.2.4 Examination of cell morphology using Hoechst staining 
Apoptotic cells are characterized by the appearance of condensed nuclear chromatin and 
fragmented nuclei. Hoechst 33342 is a fluorescent dye used to stain DNA structures in living cells. 
Normal nuclei stained with the Hoechst dye are in dimly blue, whereas apoptotic nuclei are 
demonstrated as condensed, smaller, and very intensely bright blue (Mgbonyebi et al., 1999). 
In this study, cells were seeded at 1x105/400 J.LUwell in 8-well Lab-Tek chamber slides. 
Following incubation overnight at 37 °C in a 5% C02 humidified incubator, cells were treated with 
medium containing 0.016% seal oil, 100 nM paclitaxel, 100 nM paclitaxel plus 0.016% seal oil for 
24 h, respectively. Cells were also treated with 0.016% soybean oil for 24, 48, 72 h, respectively. 
Cells treated with fresh medium under the same conditions were used as control. 
After incubation for desired periods, medium was removed and cells were washed with PBS 
twice. Then cells were fixed with ice-cold methanol at room temperature for 10 min. After being 
washed with PBS twice, fixed cells were stained with 100 J.LL of Hoechst dye in PBS (0.5 J.lg/mL) 
at room temperature for 10 min in dark. The slides were then immersed in PBS three times with 10 
min each time. The fixed cells were mounted with VectaShield® mounting reagent and covered by 
slide cover glasses. The slides were viewed and photographed at 40X magnification using an 
Olympus BX 50 fluorescence microscope at an excitation wavelength of 360-730 nm and a 
detection wavelength of 420 nm. Experiments were repeated at least three times. A minimum of 
500-1000 cells was counted in randomly selected areas and the results were expressed as the mean 
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percentage of apoptotic cells over the total number of cells counted ± SD of three separate 
experiments. 
3.2.5 Determination of DNA strand breaks using terminal 
deoxynucleotidyltransferase-mediated bio-dUTP nick-end labelling (TUNEL) assay 
Cleavage of genomic DNA during apoptosis may yield double-stranded, low molecular weight 
DNA fragments (mono- and oligonucleosomes) as well as single strand breaks of high molecular 
weight DNA. These DNA strand breaks can be identified by labelling free 3'- OH termini with 
labelled nucleotides by a terminal deoxynucleotidyl transfererase (TdT) which catalyzes 
nucleotide polymerization. The red labelled nucleotides incorporated in nucleotide polymers can 
then be detected by fluorescence microscopy. 
In this study, cells were seeded at 1x105/400 JA.Uwell in 8-well Lab-Tek chamber slides. 
Following incubation overnight, cells were treated with 0.016% seal oil, 100 nM paclitaxel or 100 
nM paclitaxel plus 0.016% seal oil, respectively, for 24 h. Cells treated with fresh medium under 
the same conditions were used as control. 
After incubation for 24 h, the medium was removed. The cells were then washed with PBS 
twice and fixed using acetone-methanol (1:1) at -20 °C for 10 min in dark. The fixed cells were 
washed with PBS twice, and 7 5 JA.L of labelled solution which consisted of TdT labelled nucleotide 
(Enzyme solution: label solution, 1: 9, In Situ Cell Death Detection Kit, Roche) was then added 
into each well. Slides were then incubated in a 5% C02 humidified atmosphere at 37 °C for 1 h in 
dark. After rinsed with PBS twice, slides were viewed and photographed by a fluorescence 
microscope at an excitation wavelength of 530-550 nm and a detection wavelength of 590 nm. 
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Five hundred to 1000 cells were counted in randomly selected areas and the results were expressed 
as the mean percentage of apoptotic cells over the total number of cells counted ± SD of three 
separate experiments. 
3.2.6 Assessment of membrane alteration using Annexin-V-Fluorescein 
(Annexin-V-FLUOS) staining 
This analysis was performed using Annexin-V-fluorescein isothiocyanate conjugate 
(Annexin-V-FITC, green dye) and propidium iodide (PI, orange dye) to differentiate apoptotic 
cells from necrotic and intact cells. 
In the early stage of apoptosis, changes occur at the cell membrane. One of the alterations is 
the translocation of phosphatidylserine (PS) from the inner side of the plasma membrane to the 
outer layer. Annexin-Vis a Ca2+ dependent phospholipid binding protein with high affinity for PS. 
This protein can hence be used as a probe for PS exposure upon the outer leaflet of the cell 
membrane when labelled with fluorescence (e.g. FITC). PI is a DNA dye, which can penetrate into 
late apoptotic and necrotic cells that have lost their membrane integrity. However, both 
Annexin-V-FITC and PI do not bind to normal cells. Therefore, simultaneous application of these 
two staining dyes can discriminate apoptotic cells characterized with high Annexin-V-FITC and 
low PI staining from necrotic cells shown with high staining of Annexin-V-FITC and PI as well as 
normal cells shown with low Annexin-V-FITC and PI staining. 
Cells were seeded at 1x105 cells/400 p.Uwell in 8-well Lab-Tek chamber slides. One day 
after seeding, cells were treated with 0.016% seal oil for 24 h, after which medium was removed, 
and cells were washed with PBS and fixed with ice-cold methanol at room temperature for 10 min. 
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Following being washed with PBS twice, fixed cells were stained with 100 ~-tUwell 
Annexin-V-FLUOS labelling solution (Annexin-V-FITC: PI: HEPES buffer, 1: 1: 50, 
Annexin-V-FLUOS Staining Kit, Roche) and incubated at room temperature for 10 min in dark. 
The slides were then covered with slide cover glasses, viewed and photographed under a 
fluorescence microscope at an excitation wavelength of 470-490 nm and a detection wavelength of 
515 nm. Photographs obtained were representative of three experiments. 
3.2. 7 Western blotting analysis of p53 and Bcl-2 protein expression 
3.2.7.1 Extraction of protein from MCF-7 and MDA-MB-231 cells 
When cells in 6-well plates grew to 80-90% confluence, they were respectively treated with 
0.016% seal oil, 100 nM paclitaxel, 100 nM paclitaxel plus 0.016% seal oil, 0.016% soybean oil or 
0.016% soybean oil plus 100 nM paclitaxel. After incubation for 24 h, medium was removed and 
cells were washed with ice-cold PBS twice. Then, 250 J-tL of ice-cold lysis buffer (50 mM tris-HCl 
pH 8.0, 150 mM NaCl, 0.02% sodium azide, 1% igepal CA-630, 0.1% SDS, 0.5% sodium 
deoxycholate, 1% PMSF ethanol solution and 0.5% aprotinin solution) was added to each well. 
The cells were scraped off and the lysate was transferred into ice chilled 1.5 mL centrifuge tubes. 
After being placed on ice for 30 min, the lysate was centrifuged at 12,000 gat 4 °C for 10 min. The 
supernatant was then transferred into another tube and stored at -80 °C until further analysis. 
3.2. 7.2 Protein quantification 
Prior to the determination of protein concentration in the extracts, 20 J-tL of reagent S 
(surfactant) from the DC protein assay kit was added to 1 mLof reagent A (alkaline copper tartrate 
solution) to eliminate the interference from the detergents in the lysis buffer. BSA stock solution 
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(1.44 Jlg/pL in pH 7.4 PBS) was diluted with lysis buffer to obtain BSA solutions at 0.09 Jlg/JlL, 
0.18 Jlg/JlL, 0.36 Jlg/JlL and 0.72 Jlg/JlL. 
Five JlL of the above BSA solutions, lysate samples or lysis buffer (blank) were respectively 
added to each well of the 96-well plates, followed by adding 25 JlL of reagent A and 200 JlL of 
reagent B (folin reagent). The plates were placed at room temperature for 15 min, and then read on 
a Bio-Rad Model 550 microplate reader at a measurement wavelength of 630 nm. The protein 
concentration in the extracts was obtained from the standard curve constructed with the standard 
BSA solutions using the Bio-Rad Microplate Manager® 4.0 software program. 
3.2.7.3 Western blotting assay 
Before the protein extracts were resolved in a discontinuous polyacrylamide gel consisted of 
a resolving gel (lower) and a stacking gel (upper), the minigel apparatus (Mini-Protean® IT 
apparatus Bio-Rad.) was assembled according to the instruction provided. To prepare 10% 
resolving gel for p53 protein assay, 3.3 mL of 30% acrylamide mix, 2.5 mL of 1.5 M Tris (pH 8.8), 
0.1 mL of 10% SDS and 4.0 mL of distilled water (dH20) were mixed; while 15% resolving gel 
used for Bcl-2 protein was prepared by mixing 5.0 mL of 30% acrylamide mix, 2.5 mL of 1.5 M 
Tris (pH 8.8), 0.1 mL of 10% SDS and 2.3 mL of dH20. The mixture was degassed under vacuum 
for 15 min, following which 0.1 mL of 10% ammonia persulphate and 4 JlL of TEMED were 
added, and the mixture was gently shaken. The mixture was then immediately added to the gap of 
the apparatus. Sufficient space was left for the stacking gel, and the acrylarnide solution was 
covered with dHzO. 
After polymerizing for 30 min, the overlay water was poured off and the top of the gel was 
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washed with dH20. Five percent stacking gel solution with 3.4 mL of dH20, 0.83 mL of 30% 
acrylamide mix, 0.63 mL of 10% SDS, 50 J1L of 10% ammonium persulfate and 5 JLL of TEMED 
was added onto the top of the polymerized resolving gel. Immediately, a clean Teflon comb was 
inserted into the stacking gel solution. The gel was then placed at room temperature for 30 min for 
polymerization. 
Protein samples (10 Jlg for p53 assay and 20 Jlg for Bcl-2 assay) were mixed at 1:1 (v/v) with 
2X SDS gel-loading buffer prepared with 200mM Tris, 4% SDS, 0.2% bromophenol blue and 20% 
glycerol, and placed in boiling water for 3 min to denature the proteins. The samples were then 
loaded into stacking gel wells and the electrophoresis was conducted at 200 volts until the 
bromophenol blue reached the bottom of the resolving gel. 
Following electrophoresis, gels were equilibrated in transfer buffer prepared with 25 mM Tris, 
192 mM glycine and 20% methanol for 30 min, and the buffer was changed twice during 
equilibration. During the equilibration period, the nitrocellulose membranes (Hybond TM ECL TM 
Amersham Biosciences) were soaked in transfer buffer for 15-30 min. Once the equilibration was 
completed, the transfer sandwich consisted of the gel and the membrane in the middle of fibre pads 
and 12 pieces of filter papers was assembled into the transfer cassette and placed in a buffer tank 
containing ice-cold transfer buffer. 
Protein transfer was performed in the ice-cold transfer buffer at 100 volts for 2 h. To ensure 
transfer was successful, the membranes were stained with Ponceau S staining solution (0.5% 
Ponceau S and 1% glacial acetic acid) for a few seconds to obtain visible pink protein bands, and 
then washed off by dH20. 
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Following transfer, the membranes were washed with dH20 twice, and immersed into 5% 
non-fat milk blocking buffer solution prepared with tris-base and Tween-20 (TBST, 0.1% 
Tween-20, 0.8% NaCl and 0.24% Tris, HCl adjusted to pH 7.6) and shaken at room temperature 
for 1 h to block the non-specific binding sites of the proteins. 
Then, after rinsed with TBST three times for 15 min each time, membranes were incubated in 
diluted primary antibody in 5% non-fat milk TBST blocking buffer (1:1000 for anti-p53, 1:500 for 
anti-Bcl-2 antibody) with shaking at room temperature overnight. 
After rinsed with TBST twice for 15 min each time, membranes were incubated in the diluted 
secondary antibody in 5% non-fat milk TBST blocking buffer (1: 1500) for 1 h. 
The membranes were then washed with TBST twice again and incubated with enhanced 
chemilumiscence ECL ™ detection solution (Amersham Biosciences) for a few seconds. Excess 
detection reagent was then drained off, and the membranes were exposed to Hyperfilm™. Finally, 
films were developed to reveal the protein bands. 
Considering that the observed changes in protein expression could be the result of different 
amounts of protein loaded, ~-actin protein was employed as the control protein. To re-probe 
~-actin with anti-~-actin mAb in the same membranes, the primary signal on the membranes was 
striped off with stripping buffer (100 mM 2-mercaptoethanol, 2% SDS and 62.5 mM Tris/HCl pH 
6.8) by occasional agitating at 50 °C for 10 min, and then the membranes were washed with TBST 
buffer twice or 10 min each time. Subsequently, the membranes were immersed into 7% non-fat 
milk TBST blocking buffer, and shaken at room temperature for 2 h to block the non-specific 
binding sites again. Finally, the membranes were incubated with diluted primary anti-~-actin mAb 
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(1:5000) in 5% non-fat milk TBST blocking buffer overnight and subsequently secondary 
antibody for 1 h. The f3-actin protein was then detected as described previously. 
The optical density (O.D.) of the protein bands was measured and quantified using Eagle Eye 
ll® Still Video System (Stratagene Co.). The relative O.D. value was calculated as: 
O.D. of protein with treatment x O.D. of B-actin without treatment (control) 
O.D. of f3-actin with treatment x O.D. of protein without treatment (control) 
Protein expression levels were then expressed as the ratio of p53 or Bcl-2 of the samples over 
control (without drug treatments). The photographs were representative of at least four separate 
experiments. The data were expressed as mean± SD. 
3.2.8 Determination of lipid peroxide products by TBARS assay 
As a result of oxidative stress, PUFAs produce lipid peroxide products such as aldehyde, 
which can react with thiobarbituric acid (TBA) to form a 2:1 pink adduct (Figure 3.1) that can be 
measured by a spectrophotometer. In this assay, malondialdehyde (MDA) was used as a standard 
to react with TBA and the amount of TBARS in samples was expressed in terms of MDA 
equivalents. 
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Figure 3.1 Structure ofMDA adduct with TBA (Adapted from TBARS Assay Kit, ZeptoMetrix) 
Cells were seeded in 25 cm2 flasks. When cells grew to 80-90% confluence, they were treated 
with 0.016% seal oil and 100 nM paclitaxel plus 0.016% seal oil for 24 h, respectively. Cells 
treated with fresh medium were used as control. After incubation for 24 h, cells were dissociated 
and lipid binding proteins were extracted as described in Section 3.2.7.1. The amount of protein 
was quantified as described in Section 3.2.7.2. 
MDA standards (2.5 nmol/mL, 5.0 nmol/mL, 7.5 nmol/mL and 10 nmol/mL) were prepared 
by diluting the MDA stock solution (100 nmollmL) with the dilution buffer provided in the kit. 
One hundred J.LL of samples and standards were respectively added to test tubes, followed by 
adding 100 J.LL of SDS solution and 2.5 mL of TEA/Buffer reagent. The test tubes were then 
incubated at 95 °C for 1 h. After incubation, the temperature of samples was allowed to return to 
room temperature before the tubes were centrifuged at 3000 RPM for 15 min. The supernatant was 
collected and read by a Beckman DU-70 spectrophotometer at a wavelength of 532 nm. Results 
were obtained from the MDA standard curve and expressed as the amount of MDA in per mg 
protein. Experiments were repeated at least three times and the values were represented as the 
mean nmol of MDA equivalents in per mg protein± SD. 
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3.2.9 Determination of lipid composition in MCF-7 and MDA-MB-231 cells by gas 
chromatographic (GC) assay 
3.2.9.1 Extraction of lipids from MCF -7 and MDA-MB-231 cells 
MCF-7 and l\IDA-MB-231 cells were seeded in 25 cm2 flasks. When cells grew to 80-90% 
confluence, they were respectively treated with 0.016% seal oil or 100 nM paclitaxel plus 0.016% 
seal oil for 24 h. Cells treated with fresh medium under the same conditions were used as control. 
After incubation for 24 h, cells were washed with PBS twice and dissociated by trypsin-EDTA 
solution, followed by centrifuging at 3000 RPM for 5 min. Supernatant was then removed, and the 
cell pellets were suspended in 0.5 mL of methanol and sonicated for 15 min. Then, 0.5 mL of 
chloroform was added and the mixture was sonicated for another 15 min. After that, 0.5 mL of 
0.88% KCl was added into the suspension and the suspension was placed at room temperature for 
2 h to allow the organic layer to separate from the aqueous layer. The organic layer (lower part) 
was then transferred to clean tubes and washed with 1 mL of methanol: dH20 (1:1). The mixture 
was centrifuged at 3000 RPM for 5 min and the aqueous portion was removed. 
3.2.9.2 Preparation of fatty acid methyl esters 
The organic layer obtained above was transferred to the transmethylation vials and was 
subjected to evaporation under N2• One mL of transmethylation reagent (94% methanol and 6% 
HCI) and a few crystals of hydroquinone were added into the vials. The vials were then placed into 
protective cylinders and put in pre-heated (65 °C) oven for 2 h. 
After the transmethylation was completed and the temperature was returned to room 
temperature, 2 mL of hexane was added, and the vials were vortex gently. The mixture was left for 
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a few seconds to allow separation, following which the hexane layer (upper part) was transferred 
to new test tubes. The remaining portion was washed with 1 mL of hexane twice and the hexane 
portions were combined. One mL of dH20 was then added into the hexane portion to dissolve any 
water-soluble impurities. The hexane part (upper layer) was then collected in new test tubes. Again, 
the water part was washed with 1 mL of hexane twice and all hexane portions were combined. The 
collected hexane was kept at -20 °C for at least 2 h to remove frozen water, and then was subjected 
to evaporation under N2. The dry lipid film was stored at -80 °C until further analysis. 
3.2.9.3 GC assay 
Prior to GC assay, the dry lipid film was dissolved in 200 p,L of CS2 and the solution was 
transferred to the GC test vials. Then, the solution was dried under N2 and 20 p,L of CS2 was added 
to dissolve each sample. The test vials were sealed tightly with caps and placed into the 
auto-sampler of a Hewlett Packard 5890 Series IT gas chromatograph equipped with Omegawax 
320 fused silica capillary column (30m x 0.32 mm ID, 0.2 p,m film thickness). The oven, inlet and 
flame ionization detector temperature of the GC instrument were respectively set at 200 °C, 240 °C 
and 260 °C. Helium-carrier gas was running at a flow rate of 1 rnUmin. The injection volume was 
10 p,L and the running time of each sample was 60 min. The split ratio was 100:1. Before running 
samples, fatty acid methyl ester standards PUFA-2 and PUFA-3 were tested by GC for peak 
identification in the chromatograms. Identification of the peaks of samples was made by the 
comparison of retention time with known standards composed of different fatty acids. Percentage 
of each fatty acid over total lipid was provided by the chromatograms. Data from at least three 
separate experiments was expressed as mean± SD. 
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3.3 Statistic analysis 
Significant differences between values obtained in a population of cells treated under 
different conditions were determined by the Student's t-test analysis with the SigmaPlot® 8.0 
software program. Differences with a value of *: P< 0.05 were considered to be statistically 
significant; those with a value of**: P< 0.01 were considered statistically very significant. 
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Chapter 4 Results 
4.1 Cytotoxicity of seal oil in MCF-7 and MDA-MB-231 cells 
4.1.1. Cytotoxicity of seal oil in MCF-7 cells 
MCF-7 cells were treated with different concentrations of seal oil ranging from 0.004% to 
0.032% for 24, 48 and 72 h, respectively. Cytotoxicity was determined using MTI assay. As 
shown in Figure 4.1, the cytotoxicity was concentration dependent, and seal oil showed 
significant toxicity to MCF-7 cells at the concentrations of 0.016% and 0.032%. It was found 
that the viability of cells treated with 0.016% and 0.032% seal oil for 24 h was decreased to 
83.9±3.7% (P<0.01) and 81.1±3.3% (P<0.01), respectively, while the cell viability was 
98.4±1.2% and 97.5±2.5% when cells were exposed to 0.004% and 0.008% seal oil under the 
same conditions. The cell viability was found to be 96.4±3.3%, 92.7±4.9%, 87.8±4.0% (P<0.05) 
and 82.8±4.8% (P<0.05), respectively, when cells were exposed to 0.004%, 0.008%, 0.016% and 
0.032% seal oil for 48 h. After 72 h, the cell viability was found to be 94.3±4.9% and 89.9±4.2% 
when cells were exposed to 0.004% and 0.008% seal oil, respectively, and 82.7±3.4% (P<0.05) 
and 72.9±4.6% (P<0.01) when cells were exposed to 0.016% and 0.032% seal oil, respectively. 
The results suggested that although the concentration of seal oil was shown to affect the cell 
viability, the incubation time did not appear to make any significant difference. 
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Figure 4.1 The cytotoxicity of seal oil in MCF-7 cells determined by MTT assay. 
Cells were treated for 24, 48 and 72 h, respectively. **: statistical significance at P<O.Ol; *: statistical 
significance at P<0.05 compared with the results of the cells treated with 0.004% seal oil. Results are 
expressed as mean ± SD from three separate experiments. 
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4.1.2 Cytotoxicity of seal oil in MDA-MB-231 cells 
MDA-MB-231 cells were also treated with different concentrations of seal oil ranging from 
0.004% to 0.032% for 24, 48 and 72 h, respectively. As shown in Figure 4.2, seal oil was toxic to 
MDA-MB-231 cells at all concentrations and time intervals tested. Following treatment for 24 h, 
the viability of cells treated with 0.016% and 0.032% seal oil was decreased to 82.7±3.1% 
(P<0.05) and 78.7±3.7% (P<0.05) from 94.3±4.4% when treated with 0.004% and 89.9±4.0% 
when treated with 0.008% seal oil, respectively. In comparison with cells treated with 0.004% 
and 0.008% seal oil for 48 h, the cell viability was significantly decreased to 73.5±0.8% (P<0.01) 
when cells were treated with 0.016% seal oil and to 72.9±3.1% (P<0.05) when treated with 
0.032% seal oil. When cells were treated for 72 h, 0.016% seal oil caused the cell viability to 
decrease to 70.1±6.1 %, and 0.032% seal oil caused the viability to decrease further to 69.4±5.3%, 
while the viability was decreased to 72.1±4.1% and 78.4±4.6% by 0.008% and 0.004% seal oil, 
respectively. 
In MDA-MB-231 cell line, the cytotoxicity of seal oil was found to have increased as the 
concentration of seal oil was increased when cells were treated for 24 and 48 h. However, when 
the cells were treated for 72 h, no significant difference of cytotoxicity was found as the 
concentration of seal oil was increased. 
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Figure 4.2 The cytotoxicity of seal oil in :MDA-MB-231 cells determined by MTT assay. 
Cells were treated for 24, 48 and 72 h, respectively. **: statistical significance at P<O.Ol; *: statistical 
significance at P<0.05 compared with the results of the cells treated with 0.004% seal oil. Results are 
expressed as mean ± SD from three separate experiments. 
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4.2 Cytotoxicity of paclitaxel in the absence and presence of seal oil in MCF-7 and 
MDA-MB-231 cells 
Both MCF-7 and !vfDA-MB-231 cell lines were treated with varying concentrations of 
paclitaxel ranging from 0.39 JLM to 400 JLM alone and in combination with 0.016% seal oil for 
24 h. In order to investigate the effect of seal oil on paclitaxel-induced cytotoxiity, MTT assay 
was employed and results are shown in Figures 4.3 and 4.4. It was found that the cytotoxicity 
induced by paclitaxel was concentration-dependent in both cell lines. The IC50 values of 
paclitaxel in MCF-7 and !vfDA-MB-231 cells were found to be 15.2 ±5.9 J.!M and 57.0 ±8.6 JJ.M, 
respectively. It was found that 0.016% seal oil enhanced the cytotoxicity ofpaclitaxel in both cell 
lines and the IC50 values were significantly decreased to 4.6 ±2.4 JJ.M (P<0.05) in MCF-7 cells 
and 24.1±2.8 J.!M (P<O.Ol) in !vfDA-MB-231 cells, respectively (Table 4.1). The increased 
cytotoxicity was found to be more remarkable at lower concentrations of paclitaxel. In addition, 
the lower IC50 value of paclitaxel in MCF-7 cells than that in !vfDA-MB-231 cells suggests that 
MCF-7 cell line is more sensitive to paclitaxel than !vfDA-MB-231 cell line. 
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Figure 4.3 Cell viability of MCF-7 cells treated with varying concentrations of paclitaxel alone 
(-•-) and in combination with 0.016% seal oil (-o-) for 24 h determined by MTT assay. 
Results are expressed as mean ± SD from three separate experiments. 
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Figure 4.4 Cell viability of MDA-MB-231 cells treated with varying concentrations of paclitaxel 
alone (-•-) and in combination with 0.016% seal oil (-o-) for 24 h determined by MIT assay. 
Results are expressed as mean ± SD from three separate experiments. 
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Table 4.1 IC50 values of paclitaxel in the absence and presence of 0.016% seal oil in MCF-7 and 
MDA-MB-231 cell lines. 
ICso (JLM) 
Cell line Paclitaxel Paclitaxel + 0.016% seal oil 
MCF-7 15.2 ±5.9 4.6 ±2.4 * 
MDA-MB-231 57.0 ±8.6 24.1 ±2.8 ** 
Results are expressed as mean ± SD from four separate experiments. Statistical significance was 
obtained by t-test as compared with paclitaxel alone treatment. *: statistical significance at 
P<0.05; **: statistical significance at P<O.Ol. 
4.3 Examination of cell morphology using Hoechst staining 
To investigate the apoptotic manifestation, cells were exposed to 0.016% seal oil, 100 nM 
paclitaxel alone or in combination with 0.016% seal oil for 24 h. Hoechst staining was used to 
assess chromatin aggregation, one of the characteristic morphological changes associated with 
apoptosis. The number of apoptotic cells in randomly selected areas was counted. A minimum of 
500-1000 cells was examined for each experiment and the results were expressed as the mean 
percentage of apoptotic cells over the total number of cells counted. Results are shown in Figures 
4.5 and 4.6, and Table 4.2. 
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Table 4.2 The percentage of apoptotic cells with morphological changes determined by Hoechst 
staining. 
Cell line Control Treated with Treated with 100 Treated with 100 nM 
0.016% seal nM paclitaxel paclitaxel+0.016% seal oil 
oil 
MCF-7 0 6.9±0.7 12.3±1.3 17.5±1.9* 
MDA-MB-231 0 6.7±1.2 8.8±1.5 13.3±2.4* 
Results are expressed as mean± SD from three separate experiments*: statistical significance at 
P<0.05 was obtained by t-test as compared with paclitaxel treatment. 
In both cell lines, chromatin aggregation, cytoplasmic and nuclear condensation 
characterized as intensively bright blue colour was observed after cells were treated with 
paclitaxel alone and in combination with 0.016% seal oil. The treatment with paclitaxel in the 
presence of seal oil was found to have induced more apoptotic cells than paclitaxel alone. It was 
also found that seal oil alone led cells to undergo early stage of apoptosis as evidenced by 
condensed chromatin. These results suggested that the increased amount of apoptotic cells 
observed with paclitaxel in combination with seal oil was likely due to the fact that seal oil itself 
could induce apoptosis. 
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Figure 4.5 Morphological changes in MCF-7 cells determined by Hoechst stmrung ( 40X 
magnification). A: control (cells without treatments); B: cells treated with 0.016% of seal oil; C: 
cells treated with 100 nM of paclitaxel alone, and D: cells treated with 100 nM of paclitaxel in 
combination with 0.016% of seal oil for 24 hrs, respectively. Photographs and data are 
representative of three separate experiments.*: statistical significance at P<0.05 compared with 
paclitaxel alone treatment. 
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Figure 4.6 Morphological changes in MDA-MB-231 cells determined by Hoechst staining (40X 
magnification). A: control (cells without treatments); B: cells treated with 0.016% of seal oil; C: 
cells treated with 100 nM of paclitaxel alone, and D: cells treated with 100 nM of paclitaxel in 
combination with 0.016% of seal oil for 24 hrs, respectively. Photographs and data are 
representative of three separate experiments.*: statistical significance at P<0.05 compared with 
paclitaxel alone treatment. 
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4.4 Determination of DNA strand breaks using TUNEL assay 
TUNEL was employed to investigate the DNA strand breaks in apoptotic cells. A minimum 
of 500-1000 cells in randomly selected areas was examined for each experiment and the results 
were expressed as the mean percentage of apoptotic cells over the total number of cells counted. 
Results are shown in Figures 4.7 and 4.8, and Table 4.3. 
Table 4.3 The percentage of apoptotic cells with DNA strand breaks determined by TUNEL. 
Cell line Control Treated with Treated with 100 Treated with 100 nM 
0.016% seal nM pacli taxel paclitaxel+0.016% seal oil 
oil 
MCF-7 0 4.0±0.5 17.3±1.4 22.1±2.3* 
MDA-MB-231 0 8.4±1.6 17.7±1.5 25.8±2.6* 
Results are expressed as mean± SD from three separate experiments.*: statistical significance at 
P<0.05 was obtained by t-test as compared with paclitaxel alone treatment. 
Figures 4.7 and 4.8 show cells with DNA fragmentation (bright orange) observed when 
cells were exposed to 100 nM paclitaxel alone and 100 nM paclitaxel in combination with 
0.016% seal oil for 24 h. In comparison with paclitaxel alone treatment, the treatment of 
paclitaxel in combination with 0.016% seal oil induced more apoptotic cells as evidenced by the 
incidence of cells showing condensed DNA fragments. Seal oil alone also led some cells to 
undergo early apoptosis with aggregation of DNA, which was consistent with the results shown 
by Hoechst staining. 
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Figure 4.7 DNA fragmentations observed in MCF-7 cells determined using TUNEL procedure 
(40X magnification). A: control (cells without treatments); B: cells treated with 0.016% of seal 
oil; C: cells treated with 100 nM of paclitaxel alone, and D: cells treated with 100 nM of 
paclitaxel in combination with 0.016% of seal oil for 24 hrs, respectively. Photographs and data 
are representative of three separate experiments.*: statistical significance at P<0.05 compared 
with paclitaxel alone treatment. 
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Figure 4.8 DNA fragmentations observed in MDA-MB-231 cells determined using TUNEL 
procedure (40X magnification). A: control (cells without treatments); B: cells treated with 
0.016% of seal oil; C: cells treated with 100 nM ofpaclitaxel alone, and D: cells treated with 100 
nM of paclitaxel in combination with 0.016% of seal oil for 24 hrs, respectively. Photographs 
and data are representative of three separate experiments.*: statistical significance at P<0.05 
compared with paclitaxel alone treatment. 
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4.5 Assessment of membrane alteration using Annexin-V-FLUOS staining 
MCF-7 and MDA-MB-231 cells treated with 0.016% seal oil for 24 h were stained with 
Annexin-V-FITC and PI to measure membrane changes. As shown in Figure 4.9, early stage of 
apoptosis with PS translocation to the outer layer of the cell membrane as evidenced by the green 
membrane was observed. Some cells were found to bind to both fluorescent dyes showing green 
membrane and orange condensed cytoplasm, which revealed that these cells were undergoing 
late stage of apoptosis with the loss of integrity of membrane and fragmented nuclei. 
When cells were treated with 100 nM paclitaxel in the absence and presence of 0.016% seal 
oil, most apoptotic cells were observed showing late stage of apoptotic characteristics with 
fragmented nuclei and loss of integrity of membrane. No distinct difference was observed 
between cells treated with paclitaxel alone and paclitaxel plus seal oil by Annexin-V-FLUOS 
staining. Since seal oil-induced apoptosis only appeared to be in its early stage as evidenced by 
PS translocation in the cell membrane according to the results of Annexin-V-FLUOS staining, it 
indicated that the ability of seal oil to induce apoptosis was much weaker than that of paclitaxel. 
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Figure 4.9 Membrane alterations of apoptotic MCF-7 and MDA-MB-231 cells determined by 
Annexin-V-FLUOS staining (40X magnification). Photographs are representative of three 
separate experiments. 
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4.6 Western blot analysis of p53 and Bcl-2 protein expression 
4.6.1 Expression of p53 and Bcl-2 proteins in MCF -7 cells 
The expression of p53 and Bcl-2 proteins was examined by Western blot assay. Figure 4.10 
and Table 4.4 show that the expression of p53 protein in MCF-7 cells was increased by 29% 
when cells were exposed to 100 nM paclitaxel for 24 h, compared with the control (P<0.05). 
However, the expression of p53 was decreased slightly by 0.016% seal oil to 90% of the control. 
The inclusion of 0.016% seal oil to paclitaxel reduced the expression of p53 to 82% of the 
control. 
As shown in Figure 4.11 and Table 4.4, the expression of Bcl-2 protein in MCF-7 cells 
treated with 100 nM paclitaxel or 0.016% seal oil was down-regulated by 40% and 27%, 
compared with the control (P<0.05), respectively. The expression of Bcl-2 protein was further 
decreased by 100 nM paclitaxel in combination with 0.016% seal oil to 35% of the control 
(P<0.01). 
Table 4.4 The expression of p53 and Bcl-2 proteins in MCF-7 cells determined by Western blot 
and expressed as O.D. values. The values represent mean± SD from four separate experiments. 
Statistical significance was obtained by t-test as compared with control. *: statistical significance 
at P<0.05; **: statistical significance at P<O.Ol. 
O.D. values Control Treated with Treated with Treated with 100 nM 
0.016% seal 100 nM paclitaxel+0.016% seal oil 
oil paclitaxel 
p53 1 0.90±0.10 1.29±0.17* 0.82±0.09 
Bcl-2 1 0.73±0.14* 0.60±0.09* 0.35±0.08** 
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Figure 4.10 The expression of p53 protein in MCF-7 cells determined by Western blot. 
C: control (cells without treatments); S: cells treated with 0.016% seal oil; T: cells treated with 100 nM 
paclitaxel alone, and ST: cells treated with 100 nM paclitaxel in combination with 0.016% seal oil for 24 h, 
respectively. *: statistical significance at P<0.05 compared with control. The O.D. values are expressed as 
mean ± SD from four separate experiments. Photographs are representative of four separate experiments. 
72 
Bcl-2 
c s T ST 
p-act in 
Bcl-2 protein expression in MCF -7 cells 
1.2 
- 1 Q 
'"' 
-= 0 ~ 
N 0.8 
I 
~ 
u 0.6 e 
Q,j 
= - 0.4 ~ 
..... 
~ 
d 0.2 
0 
c s T ST 
Figure 4.11 The expression ofBcl-2 protein in MCF-7 cells determined by Western blot. 
C: control (cells without treatments); S: cells treated with 0.016% seal oil; T: cells treated with 100 nM 
paclitaxel alone, and ST: cells treated with 100 nM paclitaxel in combination with 0.016% seal oil for 24 h, 
respectively. *: statistical significance at P<0.05; **:statistical significance at P<0.01 compared with control. 
The O.D. values are expressed as mean± SD from four separate experiments. Photographs are representative 
of four separate experiments. 
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These results suggest that the apoptosis induced by paclitaxel in MCF-7 cells was related to 
the up-regulation of p53 protein and down-regulation of Bcl-2 protein expression. Seal 
oil-induced apoptosis was likely associated with the inhibition of Bcl-2 protein expression and 
independent of p53 protein. The enhanced apoptosis by paclitaxel in combination with seal oil 
was probably related to the enhanced down-regulation of Bcl-2 protein expression. 
4.6.2 Expression of p53 and Bcl-2 proteins in MDA-MB-231 cells 
As shown in Figures 4.12 and 4.13, and Table 4.5, both p53 and Bcl-2 proteins in 
MDA-MB-231 cells were found to be down-regulated by 100 nM paclitaxel, which were 
approximately 60% and 40% of the control, respectively (P<0.01). The results suggested that 
paclitaxel-induced apoptosis in MDA-MB-231 cells was associated with the down-regulation of 
Bcl-2 protein expression, rather than through the up-regulation of p53 protein expression as the 
p53 protein in MDA-MB-231 cells was reported to be mutant and non-functional (Toillon et al., 
2002). 
Table 4.5 The expression of p53 and Bcl-2 proteins in MDA-MB-231 cells determined by 
Western blot and expressed as O.D. values. The values represent mean ± SD from four separate 
experiments. Statistical significance was obtained by t-test as compared with control. **· 
statistical significance at P<O.Ol. 
O.D. values Control Treated with Treated with 100 Treated with 100 nM 
0.016% seal nM paclitaxel paclitaxel+0.016% seal oil 
oil 
p53 1 2.01±0.14** 0.58±0.10** 0.73±0.08** 
Bcl-2 1 0.71±0.05** 0.39±0.10** 0.35±0.07** 
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The expression of p53 protein was found to be up-regulated by approximately 2-fold by 
0.016% seal oil in comparison with the control (P<0.01). However, compared with the control, 
the expression of p53 protein was reduced by about 25% when 0.016% seal oil was combined 
with 100 nM paclitaxel (P<0.01). The expression of Bcl-2 protein was found to be inhibited by 
seal oil to approximately 70% of the control (P<0.01). The inhibition of Bcl-2 expression was 
enhanced further by paclitaxel in combination with seal oil and was only 35% of the control 
(P<0.01). According to these results, it can be concluded that apoptosis induced by seal oil in 
MDA-MB-231 cell line was likely related to the down-regulation of Bcl-2 protein expression, 
and seal oil enhanced paclitaxel-induced apoptosis by down-regulating Bcl-2 protein expression 
further. 
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Figure 4.12 The expression of p53 protein in MDA-MB-231 cells determined by Western blot. 
C: control (cells without treatments); S: cells treated with 0.016% seal oil; T: cells treated with 100 nM 
paclitaxel, and ST: cells treated with 100 nM paclitaxel in combination with 0.016% seal oil for 24 h, 
respectively. **: statistical significance at P<0.01 compared with control. The O.D. values are expressed as 
mean ± SD from four separate experiments. Photographs are representative of four separate experiments. 
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Figure 4.13 The expression ofBcl-2 protein in MDA-MB-231 cells determined by Western blot. 
C: control (cells without treatments); S: cells treated with 0.016% seal oil; T: cells treated with 100 nM 
paclitaxel, and ST: cells treated with 100 nM paclitaxel in combination with 0.016% seal oil for 24 h, 
respectively. **: statistical significance at P<0.01 compared with control. The O.D. values are expressed as 
mean ± SD from four separate experiments. Photographs are representative of four separate experiments. 
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4. 7 Determination of lipid peroxide products by TBARS assay 
Both MCF-7 and MDA-MB-231 cell lines were treated with 0.016% seal oil or 100 nM 
paclitaxel in combination with 0.016% seal oil for 24 h, respectively. The lipid peroxide products 
were then measured by TBARS assay and quantified in terms of MDA equivalents, one of the 
end products of lipid peroxidation. The results are shown in Figures 4.14 and 4.15, and Table 4.6. 
Table 4.6 MDA equivalents measured in MCF-7 and MDA-MB-231 cells. 
Cell line MCF-7 MDA-MB-231 
c 0.292±0.094 0.941±0.072 
s 0.620±0.091 * 1.494±0.244 * 
ST 0.632±0.073 * 1.474±0.272 * 
C: control, S: cells exposed to 0.016% seal oil and ST: cells exposed to 100 nM paclitaxel plus 
0.016% seal oil. Data are expressed as mean± SD nmol MDNmg protein from three separate 
experiments. Statistical significance was obtained by t-test as compared to the control, *· 
statistical significance at P<0.05. 
The results show that the amounts of MDA in cells treated with seal oil were significantly 
higher than that of the control in both cell lines, with 2-fold in MCF-7 cells (P<0.05) and 1.5-fold 
in MDA-MB-231 cells (P<0.05), respectively. However, the amounts of MDA in cells treated with 
seal oil and paclitaxel in combination with seal oil were found to be similar, suggesting that 
paclitaxel had little effect on the production of lipid peroxide products. Since seal oil was found to 
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induce apoptosis and to enhance paclitaxel-induced cytotoxicity, it can therefore be concluded that 
the production of lipid peroxide products from seal oil might be responsible for the cytotoxicity 
and apoptosis caused by seal oil. 
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Figure 4.14 Lipid peroxide products in MCF-7 cells determined by TBARS assay. 
C: control (cells without treatments); S: cells treated with 0.016% seal oil, and ST: cells treated with 100 nM 
paclitaxel in combination with 0.016% seal oil for 24 h, respectively. *: statistical significance at P<0.05 
compared with control. Results are expressed as mean± SD from three separate experiments. 
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Figure 4.15 Lipid peroxide products in MDA-MB-231 cells determined by TBARS assay. 
C: control (cells without treatments); S: cells treated with 0.016% seal oil, and ST: cells treated with 100 nM 
paclitaxel in combination with 0.016% seal oil for 24 h, respectively. *: statistical significance at P<0.05 
compared with control. Results are expressed as mean ± SD from three separate experiments. 
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4.8 Lipid composition in MCF-7 and MDA-MB-231 cells determined by GC assay 
4.8.1 Lipid composition in MCF-7 cells 
The fatty acid composition of total cellular lipids was determined by GC. The fatty acids 
extracted with methanol: chloroform 1:1 (v/v) were methyl esterified using methanol: HCl (96:4 
v/v) reagent. The fatty acid methyl esters were subsequently separated through GC and identified 
by comparison of the retention times with those of the known standards. 
As shown in Table 4.7 and Figure 4.16, saturated fatty acids, e.g., palmitic acid, (16:0) and 
stearic acid, (18:0), were found to be predominant in MCF-7 cells. After cells were treated with 
0.016% seal oil for 24 h, y-LA (18:3ro-6), AA (20:4ro-6), a-LA (18:3 ro-3), EPA (20:5ro-3) and 
DHA (22:6ro-3) were detected at 0.36 ± 0.03%, 0.31 ± 0.10%, 0.14 ± 0.04%, 0.28 ± 0.06% and 
0.19 ± 0.08% of total lipids, respectively. Following the treatment with 100 nM paclitaxel in 
combination with 0.016% seal oil for 24 h, the amounts ofy-LA, AA, a-LA, EPAandDHA were 
found to be 0.34 ± 0.08%, 0.54 ± 0.04%, 0.15 ± 0.01 %, 0.22 ± 0.06% and 0.35 ± 0.05% of total 
lipids, respectively. The total amount of ro-3 PUFAs was changed from 0 in the control to 0.61 ± 
0.18% following seal oil treatment and to 0.92 ± 0.13% following paclitaxel in combination with 
seal oil treatment, respectively (P<0.05). The total amount of ro-6 PUFAs was also increased 
from 0.46 ± 0.09% in the control to 1.00 ± 0.26% in the seal oil group and 1.32 ± 0.23% in the 
paclitaxel in combination with seal oil group, respectively (P<0.05) (Figure 4.16). 
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Table 4.7 Fatty acid compositions expressed as% of total lipids in MCF-7 cells. 
Fatty acids Control Treated with Treated with 100 nM 
0.016% seal oil paclitaxel +0.016% seal 
oil 
16:0 (palmitic acid) 9.10 ± 1.68 10.12 ± 1.29 10.33 ± 1.59 
18:0 (stearic acid) 13.91 ± 0.10 17.95 ± 4.81 18.52 ± 4.31 
18:2 co-6 (LA) 0.46 ± 0.09 0.33 ± 0.13 0.44 ± 0.11 
18:3 co-6 (y-LA) ND 0.36 ± 0.03 0.34 ± 0.08 
20:4 co-6 (AA) ND 0.31 ± 0.10 0.54 ±0.04 
18:3 co-3 (a-LA) ND 0.14 ± 0.04 0.15 ± 0.01 
20:5 co-3 (EPA) ND 0.28 ± 0.06 0.22 ± 0.06 
22:5 co-3 (DPA") ND ND 0.20 ±0.01 
22:6 co-3 (DHA) ND 0.19 ± 0.08 0.35 ± 0.05 
I: co-6 0.46 ± 0.09 1.00 ± 0.26 * 1.32 ± 0.23 * 
I: co-3 ND 0.61 ± 0.18 * 0.92 ± 0.13 * 
#: DPA: docosapentaenoic acid 
ND: not detected 
Cells were treated without any drug treatment (control), treated with 0.016% seal oil and 100 nM of paclitaxel 
plus 0.016% seal oil for 24 h, respectively. Data are expressed as mean± SD from four separate experiments. *: 
statistical significance at P<0.05 compared with control. 
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Figure 4.16 The ro-3 and ro-6 fatty acids in MCF-7 cells determined by GC. 
C: control (cells without treatments); S: cells treated with 0.016% seal oil, and ST: cells treated with 100 nM 
paclitaxel in combination with 0.016% seal oil for 24 h, respectively. *: statistical significance at P<0.05 
compared with control. Results are expressed as mean ± SD from four separate experiments. 
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4.8.2 Lipid composition in MDA-MB-231 cells 
Similarly, as shown in Table 4.8 and Figure 4.17, lipids initially found in MDA-MB-231 
cells were saturated fatty acids. Following the treatment with 0.016% seal oil for 24 h, co-3 
PUFAs including a-LA (18:3co-3), EPA (20:5co-3), DPA (22:5co-3), DHA (22:6co-3) and co-6 
PUFA, y-LA (18:3co-6), were detected at 0.37 ± 0.05%, 0.16 ± 0.02%, 0.27 ± 0.01 %, 0.40 ± 
0.01% and 0.47 ± 0.12% of total lipids, respectively. The respective PUFAs were found to be 
0.42 ± 0.09%, 0.22 ± 0.09%, 0.44 ± 0.14%, 0.30 ± 0.01% and 0.47 ± 0.01% following incubation 
with 100 nM paclitaxel in combination with 0.016% seal oil. The total amount of co-3 PUFAs 
was changed from 0 in the control to 1.20 ± 0.09% following the treatment of seal oil and 1.38 ± 
0.33% following the treatment of paclitaxel in combination with seal oil, respectively (P<0.05). 
The total amount of co-6 PUFAs was also changed from 0 in the control to 0.47 ± 0.12% 
following the treatment of seal oil and 0.47 ± 0.01% following the treatment of paclitaxel in 
combination with seal oil, respectively (P<0.05) (Figure 4.17). 
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Table 4.8 Fatty acid compositions expressed as % of total lipids in MDA-MB-231 cells. 
Fatty acids Control Treated with Treated with 100 nM 
0.016% seal oil paclitaxel + 0.016% seal 
oil 
16:0 (palmitic acid) 9.17 ± 0.85 8.64 ± 2.46 8.48 ± 1.69 
18:0 (stearic acid) 16.47 ± 1.59 15.95 ± 4.19 15.70 ± 3.69 
18:2 ro-6 (LA) ND ND ND 
18:3 ro-6 (y-LA) ND 0.47 ± 0.12 0.47 ± 0.01 
20:4 ro-6 (AA) ND ND ND 
18:3 ro-3 (a-LA) ND 0.37 ± 0.05 0.42 ± 0.09 
20:5 ro-3 (EPA) ND 0.16 ± 0.02 0.22±0.09 
22:5 ro-3 (DPA) ND 0.27 ± 0.01 0.44 ± 0.14 
22:6 ro-3 (DHA) ND 0.40 ± 0.01 0.30 ± 0.01 
1: ro-6 ND 0.47 ± 0.12 * 0.47 ± 0.01 * 
1: ro-3 ND 1.20 ±0.09 * 1.38 ± 0.33 * 
ND: not detected 
Cells were treated without any treatment (control), treated with 0.016% seal oil and 0.016% seal oil plus 100 
nM paclitaxel for 24 h, respectively. Data are expressed as mean ± SD from four separate experiments. *: 
statistical significance at P<0.05 compared with control. 
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Figure 4.17 The co-3 and co-6 fatty acids in MDA-MB-231 cells determined by GC. 
C: control (cells without treatments); S: cells treated with 0.016% seal oil, and ST: cells treated with 100 nM 
paclitaxel in combination with 0.016% seal oil for 24 h, respectively. *: statistical significance at P<0.05 
compared with control. Results are expressed as mean ± SD from four separate experiments. 
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In conclusion, following the treatment of 0.016% seal oil for 24 h, the composition of lipids 
in the two cell lines tested, MCF-7 and MDA-MB-231, was found to have changed. In MCF-7 
cell line, the total co-3 PUFAs increased from 0 in the control to 0.6-1.0% of total lipids, and the 
total co-6 PUFAs increased from 0.5% in the control to 1.0-1.3% of total lipids. In MDA-MB-231 
cell line, neither co-3 nor co-6 PUFAs was detected in the control; however, following the 
treatments of seal oil, co-3 and co-6 PUFAs were detected at 1.2- 1.4% and 0.5% of total lipids, 
respectively. Since no significant difference was found in the lipid composition of the cells 
treated with seal oil and paclitaxel in combination with seal oil, it is therefore believed that 
paclitaxel had little effect on the change of the lipid composition in the cell membrane. Because 
PUFAs cannot be bio-synthesized de novo in mammalian cells, the increase of PUFAs was 
thought to be derived from the seal oil the cells were exposed to. The increase of PUFAs in the 
cells might be responsible for the elevated production of intracellular lipid peroxides, which was 
observed in the TBARS assay. 
4.9 Effect of soybean oil on cell growth, cell morphology, and expression of p53 and Bcl-2 
proteins in MCF-7 and MDA-MB-231 cells 
Intralipid® is a currently available fat emulsion on the market. It is used in clinic as a dietary 
supplement by intravenous infusion for patients who are unable to obtain enough fat in their diet 
due to certain illnesses or recent surgery, to provide energy and nutritional substances needed for 
normal functions. 
The main ingredient in Intralipid® is the purified soybean oil, which contains approximately 
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15% saturated fatty acids (palmitic acid, 16:0 and stearic acid, 18:0), 24% monounsaturated fatty 
acid (oleatic acid, 18: 1ro-9) and 61% PUPAs including more than 50% linoleic acid (18:2ro-6) 
and about 7% a-linolenic acid (18:3ro-3) (USDA, 1979). Unlike seal oil emulsion, Intralipid® 
has a higher ratio of ro-6/ro-3 and lacks long chain PUPAs such as DHA and EPA. 
To compare the effect of soybean oil on breast cancer cells with that of seal oil, MTT assay, 
Hoechst staining and Western blot assay were performed. 
4.9.1 Effect of soybean oil on MCF-7 and MDA-MB-231 cell growth 
4.9.1.1 Effect of soybean oil on MCF -7 cell growth 
MCF-7 cells were treated with different concentrations of soybean oil varying from 0.004% 
to 0.032% for 24,48 and 72 h, respectively. As shown in Figure 4.18, after the cells were treated 
with 0.004%, 0.008%, 0.016% and 0.032% soybean oil for 24 h, the cell viability was decreased 
to from 83.1±7.7% to 75.5±2.4% of the control. The cell viability was decreased further when 
cells were treated for 48 and 72 h to approximately 60% of the control (P<0.01 and P<0.05), 
compared with that for 24 h. 
In comparison with the cytotoxicity induced by seal oil in MCF-7 cells, soybean oil showed 
greater toxicity to MCF-7 cells under the same conditions. (Figures 4.19-21) 
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Figure 4.18 The effect of soybean oil on MCF-7 cells treated for 24, 48 and 72 h at different 
concentrations. 
**: statistical significance at P<O.Ol; *: statistical significance at P<0.05 compared with data of 24 h. Results 
are expressed as mean ± SD from three separate experiments. 
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Figure 4.19 The effect of seal oil and soybean oil on MCF-7 cells treated for 24 h at different 
concentrations. 
**: statistical significance at P<O.Ol; *: statistical significance at P<0.05 compared with seal oil. Results are 
expressed as mean ± SD from three separate experiments. 
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Figure 4.20 The effect of seal oil and soybean oil on MCF-7 cells treated for 48 h at different 
concentrations. 
**: statistical significance at P<O.Ol compared with seal oil. Results are expressed as mean± SD from three 
separate experiments. 
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Figure 4.21 The effect of seal oil and soybean oil on MCF-7 cells treated for 72 h at different 
concentrations. 
**: statistical significance at P<O.Ol compared with seal oil. Results are expressed as mean± SD from three 
separate experiments. 
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4.9.1.2 Effect of soybean oil on MDA-MB-231 cell growth 
MDA-MB-231 cells were treated with soybean oil as well. Figure 4.22 shows that when 
cells were treated with soybean oil varying from 0.004% to 0.032% for 24 h, the cell viability 
was found to be decreased to from 92.5±3.9% to 80.9±2.6% of the control. However, the cell 
viability was improved when cells were treated for 48 h, to more than 95% of the control 
(P<0.01). When cells were treated for 72 h, the cell viability was further increased to 115% -
140% of the control (P<0.01and P<0.05). The results suggest that instead of killing cells, 
soybean oil promoted MDA-MB-231 cell growth following incubation for 48 and 72 h. 
Compared with the cytotoxicity induced by seal oil in MDA-MB-231 cells, the cell viability 
was decreased only following the treatment of soybean oil for 24 h, and was increased following 
the treatment of soybean oil for 48 and 72 h. (Figures 4.23-25) 
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Figure 4.22 The effect of soybean oil on MDA-MB-231 cells treated for 24, 48 and 72 h at 
different concentrations. 
**: statistical significance at P<O.Ol; *: statistical significance at P<0.05 compared with data of 24 h. Results 
are expressed as mean ± SD from three separate experiments. 
95 
120 
100 
~ 
~ 80 .._... 
;;;...... 
~ 
·~ ~
·~ 
..0 60 ~ 
·~ > 
~ 
~ 
0 40 u 
20 
0 
Effect of emulsions on MDA-MB-231 cells 
at day 1 
seal oil 
• lntralipid 
0.004 0.008 0.016 0.032 
Concnentration of lipids (g/100mL) 
Figure 4.23 The effect of seal oil and soybean oil on MDA-MB-231 cells treated for 24 h at 
different concentrations. 
Results are expressed as mean ± SD from three separate experiments. 
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Figure 4.24 The effect of seal oil and soybean oil on MDA-MB-231 cells treated for 48 h at 
different concentrations. 
**: statistical significance at P<O.Ol; *: statistical significance at P<0.05 compared with seal oil. Results are 
expressed as mean ± SD from three separate experiments. 
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Figure 4.25 The effect of seal oil and soybean oil on MDA-MB-231 cells treated for 72 h at 
different concentrations. 
**: statistical significance at P<O.Ol; *: statistical significance at P<0.05 compared with seal oil. Results are 
expressed as mean± SD from three separate experiments. 
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4.9.2 Effect of soybean oil on cell morphology in MCF-7 and MDA-MB-231 cells 
Morphological changes of the cells respectively treated with 0.016% soybean oil for 24,48 
and 72 h were assessed by Hoechst staining as described previously. 
4.9.2.1 Morphological changes in MCF -7 cells 
As shown in Figure 4.26, no cells were found undergoing apoptosis when they were treated 
with soybean oil for 24 h. However, a few apoptotic cells were observed when cells were treated 
for 48 and 72 h. The results were not consistent with the cell viability results determined by MTT 
assay where soybean oil showed toxicity at all time intervals, suggesting that apoptosis was not 
the only mechanism of soybean oil-induced cell death in MCF-7 cells. 
4.9.2.2 Morphological changes in MDA-MB-231 cells 
As shown in Figure 4.27, no MDA-MB-231 cells were found to present aggregated 
chromatin and condensed cytoplasm and nuclei following the treatment of soybean oil at all the 
time intervals. It suggests that soybean oil was unable to induce apoptosis in MDA-MB-231 
cells. 
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Figure 4.26 Morphological changes in MCF-7 cells treated with soybean oil determined by 
Hoechst staining (40X magnification). A: control (cells without treatments); B: cells treated for 
24 hrs; C: cells treated for 48 hrs, and D: cells treated for 72 hrs. Photographs are representative 
of three separate experiments. 
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Figure 4.27 Morphological changes in MDA-MB-231 cells treated with soybean oil determined 
by Hoechst staining (40X magnification). A: control (cells without treatments); B: cells treated 
for 24 hrs; C: cells treated for 48 hrs, and D: cells treated for 72 hrs. Photographs are 
representative of three separate experiments. 
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4.9.3 Effect of soybean oil on the expression of p53 and Bcl-2 proteins in MCF -7 and 
MDA-MB-231 cells 
Western blotting assay was employed to detect the effect of soybean oil on the expression of 
the apoptosis markers, p53 and Bcl-2 proteins. Cells were treated with 0.016% soybean oil in the 
absence and presence of 100 nM of paclitaxel for 24 h. The proteins were extracted and 
quantified, and the electrophoresis was performed as previously described. The expression of 
p53 and Bcl-2 proteins was expressed as O.D. values and was compared with that of the control. 
4.9.3.1 Expression of p53 and Bcl-2 proteins in MCF -7 cells 
As shown in Figure 4.28 and Table 4.9, soybean oil alone had little effect on the expression 
of p53 protein in MCF-7 cells. Although the expression of p53 protein in cells treated with 
soybean oil in combination with paclitaxel was 1.42-fold of the control (P<0.05), it showed no 
significant difference with the result from the cells treated with paclitaxel alone, which was 
1.29-fold of the control. (See Table 4.4) 
As shown in Figure 4.29 and Table 4.9, Bcl-2 protein expression was found to be 
up-regulated by 40% by soybean oil (P<0.05). When cells were treated with soybean oil in 
combination with paclitaxel, the Bcl-2 protein expression was increased by 30% (P<0.05), 
although paclitaxel alone inhibited the expression by 40%. (See Table 4.4) 
These results indicated that soybean oil was unable to trigger the apoptotic protein, p53, and 
promote the expression of the anti-apoptotic protein, Bcl-2, to induce apoptosis in MCF-7 cells. 
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Figure 4.28 The expression of p53 protein in MCF-7 cells determined by Western blot. 
C: control (cells without treatments); I: cells treated with 0.016% soybean oil, and IT: cells treated with 
0.016% soybean oil in combination with 100 nM paclitaxel for 24 h, respectively. *: statistical significance at 
P<0.05 compared with control. The O.D. values are expressed as mean ± SD from four separate experiments. 
Photographs are representative of four separate experiments. 
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Figure 4.29 The expression ofBcl-2 protein in MCF-7 cells determined by Western blot. 
C: control (cells without treatments); 1: cells treated with 0.016% soybean oil, and IT: cells treated with 
0.016% soybean oil in combination with 100 nM paclitaxel for 24 h, respectively. *: statistical significance at 
P<0.05 compared with control. The O.D. values are expressed as mean ± SD from four separate experiments. 
Photographs are representative of four separate experiments. 
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Table 4.9 The expression of p53 and Bcl-2 proteins in MCF-7 cells determined by Western blot 
and expressed as O.D. values. 
O.D. values Control Treated with 0.016% Treated with 0.016% soybean oil+ 
soybean oil 100 nM paclitaxel 
p53 1 1.01±0.06 1.42±0.07* 
Bcl-2 1 1.40±0.17* 1.30±0.03* 
The results are expressed as mean ± SD from four separate experiments. Statistical significance 
was performed by the Student t-test as compared with control.*: statistical significance at 
P<0.05. 
4.9.3.2 Expression of p53 and Bcl-2 proteins in MDA-MB-231 cells 
Figure 4.30 and Table 4.10 show that soybean oil down-regulated the expression of p53 
protein (P<0.05) in MDA-MB-231 cells and such down-regulation was found to have been 
further enhanced by 100 nM of paclitaxel from 47% to 42% of the control (P<O.Ol). As shown in 
Figure 4.31 and Table 4.10, it was also found that soybean oil alone had little effect on the Bcl-2 
protein expression in MDA-MB-231 cells. The expression of Bcl-2 protein in MDA-MB-231 
cells following the treatment of soybean oil in combination with paclitaxel was found to have 
reduced to 51% of the control (P<O.Ol); however, this result was not significantly different from 
that of the cells treated with paclitaxel alone. (See Table 4.5) 
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Table 4.10 The expression of p53 and Bcl-2 proteins in MDA-MB-231 cells determined by 
Western blot and expressed as O.D. values. 
O.D. values Control Treated with 0.016% Treated with 0.016% soybean oil+ 
soybean oil 100 nM paclitaxel 
p53 1 0.47±0.22* 0.42±0.04** 
Bcl-2 1 0.93±0.14 0.51 ±0.06* * 
The results are expressed as mean ± SD from four separate experiments. Statistical significance 
was performed by the Student t-test as compared with control.*: statistical significance at P<0.05; 
**: statistical significance at P<O.Ol. 
According to these results, it can be concluded that the effect of soybean oil on cell growth 
appeared to be cell dependent and soybean oil was found cytotoxic to MCF-7 cells, but 
beneficial to MDA-MB-231 cells. Soybean oil did not result in the induction of apoptosis in 
neither of the two cell lines tested,likely due to the fact that it didn't show to trigger the 
expression of p53 protein or inhibit the expression of Bcl-2 protein. 
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Figure 4.30 The expression of p53 protein in MDA-MB-231 cells determined by Western blot. 
C: control (cells without treatments); 1: cells treated with 0.016% soybean oil, and IT: cells treated with 
0.016% soybean oil in combination with 100 nM paclitaxel for 24 h, respectively.**: statistical significance at 
P<0.01; *:statistical significance at P<0.05 compared with control. The O.D. values are expressed as mean± 
SD from four separate experiments. Photographs are representative of four separate experiments. 
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Figure 4.31 The expression of Bcl-2 protein in MDA-MB-231 cells determined by Western blot. 
C: control (cells without treatments); I: cells treated with 0.016% soybean oil, and IT: cells treated with 
0.016% soybean oil in combination with 100 nM paclitaxel for 24 h, respectively. **:statistical significance at 
P<0.01 compared with control. The O.D. values are expressed as mean± SD from four separate experiments. 
Photographs are representative of four separate experiments. 
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Chapter 5 Conclusions 
5.1 Seal oil induced cytotoxicity and apoptosis in MCF-7 and MDA-MB-231 cells 
This study showed that seal oil ranging from 0.004% to 0.032% was toxic and resulted in cell 
death in both MCF-7 cells, an estrogen-dependent breast cancer cell line, and MDA-MB-231 cells, 
an estrogen-independent breast cancer cell line. 
Apoptosis was shown to be responsible for the seal oil-induced cell death. Morphological 
changes in cells exposed to 0.016% seal oil for 24 h were observed and such changes are 
characteristic to apoptosis. In addition, DNA strand breaks and membrane alterations were also 
demonstrated. The seal oil-induced apoptosis appeared to be associated with the down-regulation 
of the expression of Bcl-2, an anti-apoptotic protein, in both cell lines. The production of lipid 
peroxides was also increased in cells treated with 0.016% seal oil for 24 h, which was 
accompanied by an increased level of PUFAs in the lipid composition in cells as determined by GC. 
These results suggested that the increased amount of intracellular PUFAs was likely responsible 
for lipid peroxide increasing, and in turn, might be responsible for the apoptosis induction. 
5.2 Seal oil enhanced paclitaxel-induced cytotoxicity and apoptosis in MCF -7 and 
MDA-MB-231 cells 
When combined with different concentrations of paclitaxel ranging from 0.39 J.LM to 400 J.LM, 
0.016% seal oil was shown to enhance the paclitaxel-induced cytotoxicity upon incubation for 24 
h in both MCF-7 and MDA-MB-231 cell lines. The IC50 values of paclitaxel were decreased 
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3.3-fold in MCF-7 cells and 2.4-fold in MDA-MB-231 cells, respectively. 
Paclitaxel (100 nM) was shown to induce apoptosis in both cell lines upon incubation for 24 h. 
The apoptosis in MCF-7 cells was accompanied by the up-regulation of p53 protein expression 
and down-regulation of Bcl-2 protein expression; whereas, the down-regulation of both p53 and 
Bcl-2 proteins were demonstrated in MDA-MB-231 cell line. More cells were found undergoing 
apoptosis and the expression ofBcl-2 was further inhibited in both MCF-7 and MDA-MB-231 cell 
lines when cells were treated with 100 nM paclitaxel in combination with 0.016% seal oil. In 
addition, the levels of PUFAs in the intracellular lipid composition and lipid peroxide products 
were shown to be elevated significantly in the cells when seal oil was included. These results 
suggested that the enhanced apoptosis by 100 nM paclitaxel in combination with 0.016% seal oil 
in comparison with 100 nM paclitaxel alone was likely due to the increased inhibition of Bcl-2 
protein expression and the increased intracellular lipid peroxide products. 
5.3 Effect of soybean oil on MCF -7 and MDA-MB-231 cells 
The effect of soybean oil on the growth of MCF-7 and MDA-MB-231 cells was found to be 
cell type-dependent. Soybean oil showed a greater cytotoxicity than seal oil in MCF-7 cells. 
However, it promoted the growth of MDA-MB-231 cells. Unlike seal oil, soybean oil did not 
induce apoptosis neither of the two cell lines based on the assessment of cell morphology. Western 
blot assay showed that soybean oil had little effect on the expression of p53 protein but increased 
the expression of Bcl-2 protein in MCF-7 cells. In MDA-MB-231 cells, the expression of mutant 
p53 protein was decreased by soybean oil but little change was observed with the expression of 
110 
Bcl-2 protein. 
In conclusion, this study suggested that seal oil rich in ro-3 PUFAs may be beneficial in 
treating breast cancer. Seal oil may be given as a dietary supplement or an adjunct therapy with 
chemotherapy to cancer patients. In addition, seal oil emulsion may have the potential to be used 
for the formulation of paclitaxel or other chemotherapeutic drugs if it indeed is proven to be 
beneficial for treating cancer conditions because it may serve as a good solvent for hydrophobic 
drugs. 
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Chapter 6 Discussion 
6.1 Experiment design and optimization 
6.1.1 Cell culture and MTT assay 
The purpose of this study was to investigate the activity of harp seal oil and its effect on 
paclitaxel-induced cytotoxicity and apoptosis in breast cancer cell lines. Because lipophilic seal oil 
is unable to be dispersed uniformly in the aqueous cell culture medium, seal oil stock emulsion 
containing 10% (w/v) of purified seal oil prepared by lipid extrusion method using high pressure 
homogenizer was employed in the experiments. In order to examine the cytotoxicity of seal oil, 
different concentrations of seal oil in cell culture medium ranging from 0.004% to 0.032% (w/v) 
were prepared by diluting seal oil stock emulsion with DMEM. MTT assay was used to measure 
the cell viability. When cells were treated with 0.004% seal oil for 24 h, it was found that the cell 
viability only slightly decreased to 98.4±0.9% in MCF-7 cell line and 94.3±3.7% in 
MDA-MB-231 cell line. Thus, concentrations below 0.004% were not tested. When the 
concentration of seal oil exceeded 0.032% in the cell culture medium, a visual flocculent and 
turbid mass was found in the medium, which was not desirable for cell growth. Therefore, 
concentrations higher than 0.032% were not studied either. 
The MTT assay is based on the conversion of the yellow MTT tetrazolium salt to a purple 
formazan product by the living cells, which is reflected through the absorbance read by 
spectrometry. To quantify the living cells properly, the absorbance should be linear with the 
amount of living cells. It was found that there was a linear relation between the number of cells 
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seeded at 0.2- 0.5 x 105 cells/100 JLUwell in 96-well plates and the absorbance read at 570 nm 
with a reference wavelength of 630 nm. Hence, 0.5 x 105 cells/100 JLUwell were seeded in 96-well 
plates for the M1T assay. 
6.1.2 Cytotoxicity of DMSO 
Paclitaxel is a highly hydrophobic compound. In this study, DMSO was used as a solvent to 
dissolve paclitaxel. It has been previously determined (Butt, 2004) that 0.5% (v/v) of DMSO in 
cell culture medium causes little toxicity to the cells, while it is sufficient to keep paclitaxel 
dissolved in DMEM. Hence, prior to each experiment, paclitaxel stock solutions (100 mM or 100 
JLM in DMSO stored at -20 °C) were diluted with DMEM and the concentration of DMSO was 
kept below 0.5% in all working solutions. In order to avoid any potential interaction between 
DMSO and seal oil in studies where a combination of seal oil and paclitaxel was used, paclitaxel in 
DMSO solution and seal oil were mixed by DMEM just prior to the experiments. 
6.1.3 Apoptosis 
Cytotoxic agents often induce only a fraction of cells to become apoptotic (Saunders et al., 
1997). It was demonstrated in this study that the amount of apoptotic cells determined by Hoechst 
staining and TUNEL was less than the mortality detected by MTT assay. The induction of 
apoptosis caused by cytotoxic agents is usually concentration and time dependent. It has been 
reported that the apoptotic responses to paclitaxel are often observed at 10 to 500 nM (McCloskey 
et al., 1996, Saunders et al., 1997 and Huang et al., 1997), which are 100 to 1000-fold below those 
that are effective against breast cancer cells and bring about non-specific necrotic cell death 
(Saunders et al., 1997). 
113 
In our lab, it has been previously determined that 100 nM of paclitaxel induced efficient 
apoptosis in MCF-7 and MDA-MB-231 cells upon incubation for 24 h (Butt, 2004). In this study, 
higher concentrations of paclitaxel including the IC50 concentrations and longer incubation periods 
i.e., 48 and 72 h were examined. However, under these conditions, the majority of cells underwent 
necrosis and the characteristics of apoptosis were not demonstrated. Therefore, in order to examine 
the apoptosis induced by paclitaxel, 100 nM paclitaxel and incubation of 24 h were chosen for 
subsequent studies. Based on the cytotoxicity results, seal oil at 0.016% showed significant 
toxicity to cells upon incubation for 24 h, resulting in approximately 20% of cell death. This 
concentration did not cause any visual flocculent phenomenon in the medium. Therefore, 0.016% 
seal oil was used to investigate the effect of seal oil on paclitaxel-induced apoptosis. 
Apoptosis is a highly programmed process and apoptotic cells are associated with unique 
morphological and biochemical characteristics. Apoptosis starts with the alteration of cell 
membrane with no compromise in integrity, i.e., the translocation of PS from the inner side of the 
plasma membrane to the outer layer. And then chromatin aggregation at the nuclear membrane, 
condensation of the nucleus and shrinking of cytoplasm occur. Apoptosis ends with cell 
fragmentation into apoptotic bodies. Various methods developed based on these changes are used 
to evaluate the occurrence and/or progress of apoptosis. In this study, Hoechst staining that detects 
chromatin aggregation, TUNEL that assesses DNA fragmentation and Annexin-V-FLUOS assay 
that measures membrane alteration were performed to evaluate apoptotic changes occurred. 
In addition to determining the membrane alteration in apoptotic cells upon fluorescence 
microscopy, Annexin-V-FLUOS assay can discriminate and quantify cells in difference stages 
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using flow cytometry. The simultaneous application of two staining dyes, Annexin-V-FITC and 
PI, can discriminate normal cells which would be Annexin-V-FITC negative and PI negative, 
from apoptotic cells which would appear Annexin-V-FITC positive and PI negative, and necrotic 
cells which would be Annexin-V-FITC positive and PI positive. Through a flow cytometer, the 
cells in the three stages can be clearly demarcated and quantified with different clusters. 
However, in this study, both MCF-7 and MDA-MB-231 cells are adherent cells. In order to apply 
the technology of flow cytometry properly, cells need to be dissociated from the surface of cell 
culture plates and suspended in test tubes. Trypsinization and any other sample processing 
methods may result in false positive staining due to the inevitable occurrence of cell death. 
Therefore, flow cytometry was not applied to quantify the apoptotic cells in these two types of 
adherent cell lines in this study. 
6.2 Effects of seal oil and soybean oil on breast cancer cells 
6.2.1 Apoptosis caused by seal oil 
In this study, it was found that seal oil-induced apoptosis was accompanied by the 
down-regulation of Bcl-2 protein expression and increase of lipid peroxide generation. This 
suggests that there might be a relation between the lipid peroxidation and some organelles that are 
involved in seal oil-induced apoptosis such as mitochondria. 
Mitochondria are considered as powerhouses for the vast majority of 0 2 consumption and 
believed to be a major site of ROS production during respiration because electron transport 
throughout the mitochondrial respiratory chain is extraordinarily efficient. On the other hand, 
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mitochondrial dysfunction is one of the characteristics of apoptosis. Vladimir (Vladimir, 1996) 
suggested the opening of transition permeability pores of mitochondria upon apoptosis. It was 
reported that increased 0 2 consumption in mitochondria might increase the amount of ROS 
production, while increased ROS levels would induce the opening of transition permeability pores 
of mitochondria. Maintaining the pore opening requires membrane potential (~'I'm). When ROS 
accumulates in mitochondria, long-term pore opening causes the membrane potential to collapse, 
preventing the uptake and retaining of precursors by the mitochondria for protein synthesis. In 
addition, long-term pore opening also causes imbalanced osmosis between the mitochondrial 
matrix and the intermembrane space because the pores are permeable for certain compounds with 
low molecular weights. As a result, the outer membrane would swell and burst. Consequently, 
proteins including pro-apoptotic factors such as cytochrome c and apoptosis-inducing factors (AIF) 
located in the intermembrane space would be released into the cytosol. When the pro-apoptotic 
factors reach a sufficient amount in the cytosol, apoptosis would be initiated and morphological 
changes would occur, leading to the elimination of ROS-producing cells by apoptosis (Vladimir, 
1996). Thus, mitochondria are believed to be involved in ROS-induced apoptosis by releasing 
various classes of apoptotic molecules from the intermembrane space. 
It has been reported that Bcl-2, Bax and Bcl-XL proteins are able to form ion channels and 
pores with different conformations in the membrane (Fisher, 2001). In mitochondrial membrane, 
Bcl-2 protein interacts with the permeable pores and controls pore conformation. By forming 
pores, Bcl-2 protein can maintain the ~'I'm of mitochondrial membrane and prevent the membrane 
from disruption, impeding the release of apoptotic factors from mitochondria (Petit et al., 1996). 
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Pro-apoptotic member Bax localizes largely in the cytosol, but following exposure of apoptotic 
stimuli, Bax inserts into the membrane of mitochondria to form homodimers and heterodimers. 
Translocated Bax might decrease Bcl-2 protein expression by forming heterodimers with Bcl-2 
thereby abrogating Bcl-2 capability. In addition, Bax homodimers can form selective channels and 
result in increased plasma membrane permeability, inducing the loss of ~\jim, and allowing 
cytochrome c and AIF escape into cytoplasm to activate downstream caspases to execute apoptosis 
(Reed, 1998 and Hersey et al., 2003). 
In this study, seal oil-induced apoptosis accompanied by the down-regulation of Bcl-2 protein 
expression might be associated with the dysfunction of mitochondria, as seal oil rich in highly 
unsaturated PUFAs was an exogenous source of ROS in cells. The constant stimulation of seal 
oil-produced ROS might destroy the normal mitochondrial function, resulting in the release of the 
pro-apoptotic factors into cytoplasm. These factors are able to induce nuclear chromatin 
condensation and fragmentation, which were observed under fluorescence microscopy. 
Additionally, they might trigger some of the cascades to inhibit Bcl-2 protein expression. Under 
the apoptotic stimulation, the expression of Bcl-2 protein might be also inhibited by forming 
heterodimers with Bax protein which translocated from cytoplasm to the membrane of 
mitochondria. 
6.2.2 Bcl-2 protein, lipid peroxidation and apoptosis 
Bcl-2 protein has been suggested to possess antioxidant ability (Halder et al., 1995 and 
Tyurina et al., 1997). The majority of Bcl-2 protein localizes as a membrane protein to the 
intracellular sites where oxygen free radicals are generated including mitochondria, endoplasmic 
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reticulum and nuclear membrane (Hockenbery et al., 1993). In mitochondria, for example, Bcl-2 
protein has a patchy distribution linked to the contact sides between the outer and the inner 
membrane (Petit et al., 1996), which is likely associated to its property as an antioxidant to inhibit 
apoptosis by suppressing the formation and effect of ROS. 
Lipid peroxidation in mitochondria is initiated by hydrogen extraction of OH· radical and 
other potential ROS. A conjugated diene resulted then acts with 0 2 to form a peroxy radical ROO·, 
which extracts H· from another fatty acid to establish an autocatalytic free radical chain reaction. 
The production of hydroxyl radicals results in hydrogen extraction, hydrogen addition, and 
electron transfer, which mediates the lipid peroxidation and oxidative damage to DNA and 
sulfhydryl modification of proteins (Lee et al., 2004). Bcl-2 protein may decrease the generation 
or increase the scavenging of the ROS by functioning as a direct radical scavenging protein and an 
inhibitor of electron transfer in the mitochondria inner membrane (Kane et al., 1993), thus 
decreasing the formation of ROS in order to prevent their damages. 
The fact that Bcl-2 protein acts as an antioxidant and scavenging protein against oxidative 
stress that mediates cytotoxicity implies that there might be a balance among the level of Bcl-2 
protein expression, exogenous PUFAs and the generation of lipid peroxide products. When cells 
were treated with seal oil, the redox balance might be affected by the exogenous PUFAs. With the 
increase of intracellular lipid peroxide produced by PUFAs, ROS would become predominant and 
the equilibrium might shift to the anti-oxidative side to suppress Bcl-2 activity and enhance lipid 
peroxidation, leading to the down-regulation of Bcl-2 protein expression and the occurrence of 
apoptosis. 
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In addition to changing the redox equilibrium, it is reported that peroxide products of some 
free PUFAs can also prevent Bcl-2 protein expression through binding Bcl-2 oncogenes or 
affecting other oncogenes such as suppressing ras and enhancing fas expression to block the 
trigger of Bcl-2 expression (Das, 1999). 
Taken together, exogenous PUFAs can enhance lipid peroxidation and generate abnormal 
signalling species including free radicals and various oxidized fatty acid products, causing 
mitochondrial dysfunction and the release of pro-apoptotic factors. As a consequence, the 
signalling species suppress the expression of the anti-apoptotic Bcl-2 protein by inducing the 
formation of heterodimers with Bax protein, interrupting the redox equilibrium and affecting the 
oncogenes which are capable of triggering Bcl-2 gene expression. 
Down-regulation of Bcl-2 protein is regarded as a strategy in the therapy of cancers because 
overexpression of Bcl-2 protein is a common problem and is also one of the mechanisms causing 
drug resistance. The fact that seal oil inhibited Bcl-2 protein expression indicates that it might be a 
promising agent in improving the response to chemotherapeutic drugs during cancer treatments. 
6.2.3 Promising role of seal oil on chemotherapeutic and hormonal therapy in breast cancers 
In this study, seal oil not only showed cytotoxicity in both MCF-7 and MDA-MB-231 cell 
lines, but also enhanced the cytotoxicity of paclitaxel in these cell lines, as evidenced by the 
greater toxicity of paclitaxel with lower IC50 values in combination with seal oil than paclitaxel 
alone. Since several receptors and transporters which are involved in the uptake of extracellular 
nutritional substances and drug molecular are located in the membrane, the accumulation of 
PUFAs derived from seal oil in cell membrane might alter the normal barrier function and the 
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physical and biochemical characteristics of the receptors and transporters located. It has been 
reported that in DU-145 prostate cell line, free PUFAs such as EPA, AA and OA were found to 
have a high affinity for androgen receptor (AR) and significantly decrease the binding of AR with 
androgen in DU-145 cells treated with PUFAs (Prinsloo et al., 2002). In MCF-7 cells treated with 
DHA, it was found that the binding capacity and affinity for estrogen with the receptors was 
decreased by DHA and the decrease was in a DHA dose-dependent manner (Borras et al., 1992). 
The change of biochemical properties of the receptors might lead to the alteration of intracellular 
signal transfer and cell survival. In addition, the accumulation of PUFAs in the membrane may 
also increase the membrane permeability so that higher intracellular concentration of drugs could 
be reached resulting in higher sensitivity and lower drug resistance of the cells. 
co-3 PUFAs were reported to be able to alleviate the resistance against endocrine therapy as 
well. Breast cancer with tamoxifen resistance has been found to have high activity of Akt, a 
downstream mediator in the protein kinase signalling pathway. Activation of Akt endows breast 
cancer with aggressiveness and resistance to the hormone- and chemotherapy-induced apoptosis. 
Cells with high Akt activity have also been reported to be resistant to cytotoxic agents such as 
paclitaxel and doxorubicin (deGraffenried et al., 2003). co-3 PUFAs have been proven to be potent 
and effective broad-spectrum protein kinase inhibitors. When employed to tamoxifen-resistant 
breast cancer cells with hyperactive Akt, EPA restored tamoxifen's activity against breast cancer 
cell growth, and significantly inhibited Akt kinase activity (deGraffenried et al., 2003). Based on 
these reports and the results in this study, it is therefore supposed that seal oil rich in long chain co-3 
PUFAs such as DHA and EPA may be useful for the tamoxifen and paclitaxel-resistant breast 
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cancers to improve the therapeutic efficiency. 
6.2.4 Effect of soybean oil on breast cancer cells 
In this study, soybean oil, which contains high amounts of ro-6 PUFAs (mainly LA), exhibited 
different effects on the two cell lines. It was found to be cytotoxic to MCF-7 cells but beneficial to 
MDA-MB-231 cell growth. It has been reported that LA stimulated the proliferation of mammary 
epithelial cells in vitro in the presence of epidermal growth factor (EGF) (Bandyopadhyay et al., 
1987 and 1988). EGF is one of the growth factors to modulate the proliferative effects. Mammary 
epithelial cells with hormone-independent phenotype such as MDA-MB-231 cells have an 
increased expression of EGF-R and increased level of EGF replacing ER and estrogen (Clarke et 
al., 1989). In this study, the effect of soybean oil on MDA-MB-231 cell growth might be ascribed 
to the higher level ofEGF found in MDA-MB-231 cells in comparison to that in MCF-7 cells. In 
addition, unlike MCF-7 cells, MDA-MB-231 cells are known to possess efficient ~6 and ~4 
desaturase activity and lipoxygenase activity (Rose, 1997); therefore, the high level of LA from 
soybean oil could have high tendency to undergo desaturation, elongation, to form AA and 
consequently subject to eicosanoid metabolism in MDA-MB-231 cells. Since AA and the 
eicosanoid metabolites are believed to stimulate tumour cells growth, MDA-MB-231 cell growth 
induced by soybean oil might be likely a result of the elevated AA metabolism. 
6.3 Comparison ofMCF-7 and MDA-MB-231 breast cancer cells 
6.3.1 Sensitivity to paclitaxel 
In this study, the MCF-7 breast cancer cell line was chosen to represent estrogen-dependent 
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cells with wild-type p53 protein, while the MDA-MB-231 cell line represents 
estrogen-independent cells with mutant p53 protein. MIT assay results indicated that the MCF-7 
cell line was more sensitive to paclitaxel than the MDA-MB-231 cell line which had a lower ICso 
value. One of the possible reasons could be that MCF-7 cells have a relatively low proliferation in 
the medium without additional estrogen supplement, and the treatment with paclitaxel further 
deteriorates the conditions for the cell growth, causing more MCF-7 cell death. This fact makes it 
understandable that the depletion of estrogen is a strategy of treating estrogen-dependent breast 
cancers, and in clinic, anti-hormone therapy such as using tamoxifen or androgen to antagonize 
estrogen with adjuvant chemotherapy has been applied as a treatment for patients with 
estrogen-dependent breast cancers (Mamounas et al., 2001). 
6.3.2 Effect of paclitaxel and seal oil on the expression of p53 protein 
Wild-type p53 gene is a pro-apoptotic gene as well as DNA repair gene. It exerts most of its 
tumour suppressing activity through transcriptional activation of target genes. As a 
sequence-specific transcription factor, wild-type p53 gene binds to specific DNA as a tetramer 
and activates transcription of cell cycle arrest (Gartel et al., 2002). It has been reported that about 
50% of breast tumours experience p53 mutations (Bautista et al., 1997 and Hartman et al., 1997). 
Most p53 gene mutations are in the hydrophobic mid-region of the protein with missense points. 
For example, the majority of p53 mutations are with T:A or C:G trans versions from G:C. These 
transversions produce missense proteins with altered or absent transcriptional regulation 
activities and high concentrations of p53 protein detectable by immunohistochemmistry 
(Hartman et al., 1997) as compared with wild-type p53 protein having an extremely short 
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half-life and small amount present in the cell nucleus (Bautista et al., 1997). Mutant p53 protein 
can also block wild-type p53 function by forming oligomers to abrogate the effect. The loss of 
p53 function eliminates the growth arrest in the G 1 to S phase transition which is in response to 
certain DNA damage, and enhances the frequency of damaged gene amplification (Hartman et 
al., 1997). Cells bearing defective p53 proteins bypass these checkpoints and progress through 
cell cycle with damaged DNA leading to the accumulation of unhealed chromosomal genome. 
Meanwhile, p53 mutations emerging during malignant progression in tumours leads to 
resistance to certain anticancer treatments, especially to those with radiotherapy and 
DNA-damaging agents such as doxorubicin (Bunz et al., 1999 and Gartel et al., 2002). 
The Western blot study showed that the expression of p53 protein in MCF-7 cells was 
elevated by paclitaxel, suggesting that the wild-type p53 protein was involved in the 
paclitaxel-induced apoptosis in MCF-7 cell line. According to this result, it can be seen that 
paclitaxel plays roles on the entire MCF-7 cell cycle as it can not only induce necrosis by causing 
the polymerization of tubulin and sustained mitotic block in the late 02 or M phases of the cell 
cycle, but also induce apoptosis by triggering wild-type p53 expression to arrest cell cycle in the 
G 1 to S phase. 
The expression of mutant p53 protein in MDA-MB-231 cells was attenuated by paclitaxel. 
However, whether the decrease is associated with the paclitaxel-induced apoptosis is not clear. 
The expression of the wild-type p53 protein was not increased by seal oil in MCF-7 cells 
although the ROS generated from PUFAs were expected to damage many subcellular structures 
including DNA, which could trigger the expression of p53 protein. On the other hand, seal oil was 
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found to increase the expression of mutant p53 protein in MDA-MB-231 cells. These results 
suggested that the seal oil-induced apoptosis in MCF-7 cells might be independent of p53 protein 
pathway. 
6.3.3 Uptake of PUFAs from seal oil in the extracellular environment 
The occurrence, development and proliferation of breast cancer not only need hormone 
stimuli but also other growth factors. Studies have demonstrated that both low- and high-density 
lipoproteins affect the proliferation of breast cancer cells in cell culture (Rotheneder et al., 1989 
and Stranzl et al., 1997). The lipoproteins can bind to the glycoprotein receptor present in most 
types of cells in the cytosolic and nuclear fractions to form ligand-receptor complex. The 
complex stimulates protein synthesis and secretion for cell growth (Prinsloo et al., 2002). 
Although MDA-MB-231 cell line is an estrogen receptor negative cell line, it has other factors 
attributed to the development and progression of malignancy. For example, it has a higher level 
of an otherwise regulated gene, low-density lipoprotein receptors (LDL-R) mRNA than that in 
MCF-7 cells (Rotheneder et al., 1989 and Stranzl et al., 1997). It also exhibits a higher affinity 
for low-density lipoproteins in comparison to MCF-7 cells (Rotheneder et al., 1989). As a result, 
MDA-MB-231 cells can take up sufficient low-density lipoproteins, the carrier of cholesterol 
and other growth factors in plasma, to meet the need for significant proliferation (Rotheneder et 
al., 1989). 
PUFAs are precursors of steroidal hormones, and participate in the biosynthesis of some 
hormone derivatives, e.g., prostaglandin series. In the cell culture medium containing FBS, PUFAs 
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might be taken up by binding to proteins such as albumin and are transported through binding to 
the ERs and/or LDL-Rs. Thus, PUFAs have the tendency to compete with other necessary 
nutritional substances for cell growth, thereby blocking the receptors and transporters. 
According to the results of GC assay, intracellular lipid composition change was different in 
these two cell lines. The increase of co-3 PUFAs in MCF-7 cells was lower than that in 
MDA-MB-231 cells while the increase of co-6 PUFAs in MCF-7 cells was relatively more than that 
in MDA-MB-231 cells. These differences indicate that the manner of PUFAs uptake and transport 
varies with different types of cell lines. In addition, from the cytotoxicity assay of seal oil, it can be 
seen that the two cell lines showed different sensitivities to seal oil, with MDA-MB-231 cell being 
more sensitive; suggesting that the cell sensitivity towards the PUFAs treatment was cell-type 
dependent and it might be attributed to the different receptors and transporters the cells possess. 
6.3.4 Progression from estrogen-dependent to estrogen-independent growth in human breast 
cancers 
The major problem in breast cancer therapy is that the treatments can cause changes that 
result in alteration of tumours in response to chemotherapeutical drugs and hormones. Many breast 
tumours with low metastatic potential initially express estrogen receptors and demonstrate high 
response to endocrine treatments, but ultimately lose estrogen-dependence and exhibit metastatic 
phenotype and resistance to endocrine treatments, revealing inevitable progression from 
estrogen-dependent to estrogen-independent growth (Clarke et al., 1989). The potential 
mechanisms which could contribute to the progression of human breast cancer include growth 
factor production, increased sensitivity to growth factor and overexpression of oncogenes which 
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are associated with a more malignant phenotype. Dickson et al. (Dickson et al., 1986) have 
presented that in an ovariectomized athymic nude mice model, some growth factor activities such 
as insulin-like growth factor I (IGF-I) activity and transforming growth factor a (TGF-a) like 
activity that binds to the epidermal growth factor receptor were completely stimulated by 
exogenous estrogen and sufficient to promote MCF-7 cells to form tumours. It is of note that these 
induced growth factors are partially capable of replacing estrogen, acting as estrogen-induced 
"second messengers" in estrogen responsive growth of human breast cancer, which might promote 
tumorigenesis (Dickson et al., 1986). In addition, Reed et al. (Reed et al., 1989 and Berkenstam et 
al., 1989) reported that in MCF-7 cells, estrogen could reduce ER level and ER mRNA expression 
in a dose and time dependent manner, causing the loss of estrogen-dependence with long-term 
estrogen stimuli (Reed et al., 1989 and Berkenstam et al., 1989). Furthermore, without estrogen, 
estrogen-dependent cells have a potential to convert into malignant phenotype as well. 
Katzenellenbogen et al. (Katzenellenbogen et al., 1987) reported that MCF-7 cells grown in 
absolute estrogen-free medium (5% charcoal-dextran-treated calf serum phenol red medium) 
maintained a reduced rate of cell proliferation in a one month treatment, whereas they showed a 
markedly increased rate of cell proliferation in during a 5-6 month treatment. This change in 
growth pattern might reflect altered regulation or sensitivity of growth factor in the cancer cells so 
that the cells could adapt to grow in the medium in the absence of estrogen. Cho et al. (Cho et al., 
1991) isolated an estrogen-independent MCF-7 subline from the parental estrogen-dependent 
MCF-7 cells after long term growth in vitro in the absence of estrogen. The authors demonstrated 
through this MCF-7 subline that the progression to estrogen-independent growth was 
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accompanied with a change in the regulation of some estrogen-induced genes such as pS2 gene, 
which is a useful marker under the direct control of estrogen in MCF-7 cells for estrogen 
responsiveness. 
It is therefore suggested that estrogen-dependent cell line can change to estrogen-independent 
phenotype under certain conditions with long-term estrogen stimulation or absolute absence of 
estrogen due to the alteration of regulation of various growth factors. These observations aid to 
understand that estrogen-dependent breast cancer in patients may convert into malignant 
phenotype and the antiestrogen therapy in clinic causes resistance after long-term treatment. 
Currently, adjuvant therapy with hormonal therapy and systemic chemotherapy has been accepted 
as a strategy in breast cancer treatments, to prevent the local disease from progression to metastasis 
or to treat micrometastases before progression (Buzdar, 2001 and Mamounas et al., 2001). 
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